Hubbry Logo
Organ donationOrgan donationMain
Open search
Organ donation
Community hub
Organ donation
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Organ donation
Organ donation
from Wikipedia

The National Donor Monument, Naarden, the Netherlands

Organ donation is defined as the process when a person authorizes an organ of their own to be removed and transplanted to another person, legally, either by consent while the donor is alive, through a legal authorization for deceased donation made prior to death, or for deceased donations through the authorization by the legal next of kin.

Donation may be for research or, more commonly, healthy transplantable organs and tissues may be donated to be transplanted into another person.[1][2]

Common transplantations include kidneys, heart, liver, pancreas, intestines, lungs, bones, bone marrow, skin, and corneas.[1] Some organs and tissues can be donated by living donors, such as a kidney or part of the liver, part of the pancreas, part of the lungs or part of the intestines,[3] but most donations occur after the donor has died.[1]

In 2019, Spain had the highest donor rate in the world at 46.91 per million people, followed by the US (36.88 per million), Croatia (34.63 per million), Portugal (33.8 per million), and France (33.25 per million).[4]

As of February 2, 2019, there were 120,000 people waiting for life-saving organ transplants in the United States.[5] Of these, 74,897 people were active candidates waiting for a donor.[5] While views of organ donation are positive, there is a large gap between the numbers of registered donors compared to those awaiting organ donations on a global level.[6]

To increase the number of organ donors, especially among underrepresented populations, current approaches include the use of optimized social network interventions, exposing tailored educational content about organ donation to target social media users.[7] August 13 is observed as World Organ Donation Day to raise awareness about the importance of organ donation.[8]

Process in the United States

[edit]

Organ donors are usually dead at the time of donation, but may be living. For living donors, organ donation typically involves extensive testing before the donation, including psychological evaluation to determine whether the would-be donor understands and consents to the donation. On the day of the donation, the donor and the recipient arrive at the hospital, just like they would for any other major surgery.[9]

For dead donors, the process begins with verifying that the person is undoubtedly deceased, determining whether any organs could be donated, and obtaining consent for the donation of any usable organs. Normally, nothing is done until the person has already died, although if death is inevitable, it is possible to check for consent and to do some simple medical tests shortly beforehand, to help find a matching recipient.[9]

The verification of death is normally done by a neurologist (a physician specializing in brain function) that is not involved in the previous attempts to save the patient's life. This physician has nothing to do with the transplantation process.[9] Verification of death is often done multiple times, to prevent doctors from overlooking any remaining sign of life, however small.[10] After death, the hospital may keep the body on a mechanical ventilator and use other methods to keep the organs in good condition.[10] The donor's estate and their families are not charged for any expenses related to the donation.[11]

The surgical process depends upon which organs are being donated. The body is normally restored to as normal an appearance as possible, so that the family can proceed with funeral rites and either cremation or burial.

The lungs are highly vulnerable to injury and thus the most difficult to preserve, with only 15–25% of donated organs used.[12]

History

[edit]

The first living organ donor in a successful transplant was Ronald Lee Herrick (1931–2010), who donated a kidney to his identical twin brother Richard (1931–1963) in 1954.[13] The lead surgeon, Joseph Murray, and the nephrologist, John Merrill, won the Nobel Prize in Physiology or Medicine in 1990 for advances in organ transplantation.

The youngest organ donor was a baby with anencephaly, born in 2014, who lived for only 100 minutes and donated his kidneys to an adult with renal failure.[14] The oldest known cornea donor was a 107-year-old Scottish woman, whose corneas were donated after her death in 2016.[15] The oldest known organ donor for an internal organ was an Italian woman, who donated her liver after she died in 2022 in Florence at the age of 100 years, 10 month and one day.[16][17]

The oldest altruistic living organ donor was an 85-year-old woman in Britain, who donated a kidney to a stranger in 2014 after hearing how many people needed to receive a transplant.[18]

Researchers were able to develop a novel way to transplant human fetal kidneys into anephric rats to overcome a significant obstacle in impeding human fetal organ transplantations.[19] The human fetal kidneys demonstrated both growth and function within the rats.[19]

Brain donation

[edit]

Donated brain tissue is a valuable resource for research into brain function, neurodiversity, neuropathology and possible treatments. Both divergent and healthy control brains are needed for comparison.[20] Brain banks typically source tissue from donors who had registered with them before their death,[21] since organ donor registries focus on tissue meant for transplantation. In the United States the nonprofit Brain Donor Project facilitates this process.[22][23]

Legislation and global perspectives

[edit]

The laws of different countries allow potential donors to permit or refuse donation, or give this choice to relatives. The frequency of donations varies among countries.

[edit]

The term consent is typically defined as a subject adhering to an agreement of principles and regulations; however, the definition becomes difficult to execute concerning the topic of organ donation, mainly because the subject is incapable of consent due to death or mental impairment.[24] There are two types of consent being reviewed; explicit consent and presumed consent. Explicit consent consists of the donor giving direct consent through proper registration depending on the country.[25] The second consent process is presumed consent, which does not need direct consent from the donor or the next of kin.[25] Presumed consent assumes that donation would have been permitted by the potential donor if permission was pursued.[25] Of possible donors an estimated twenty-five percent of families refuse to donate a loved one's organs.[26]

Opt-in versus opt-out

[edit]

As medical science advances, the number of people who could be helped by organ donors increases continuously. As opportunities to save lives increase with new technologies and procedures, the demand for organ donors rises faster than the actual number of donors.[27] To respect individual autonomy, voluntary consent must be determined for the individual's disposition of their remains following death.[28] There are two main methods for determining voluntary consent: "opt in" (only those who have given explicit consent are donors) and "opt out" (anyone who has not refused consent to donate is a donor). In terms of an opt-out or presumed consent system, it is assumed that individuals do intend to donate their organs to medical use when they expire.[28] Opt-out legislative systems dramatically increase effective rates of consent for donation as a consequence of the default effect.[29] For example, Germany, which uses an opt-in system, has an organ donation consent rate of 12% among its population, while Austria, a country with a very similar culture and economic development, but which uses an opt-out system, has a consent rate of 99.98%.[29][30]

Opt-out consent, otherwise known as "deemed" consent, support refers to the notion that the majority of people support organ donation, but only a small percentage of the population are actually registered, because they fail to go through the actual step of registration, even if they want to donate their organs at the time of death. This could be resolved with an opt-out system, where many more people would be registered as donors when only those who object consent to donation have to register to be on the non-donation list.[28]

For these reasons, countries, such as Wales, have adopted a "soft opt-out" consent, meaning if a citizen has not clearly made a decision to register, then they will be treated as a registered citizen and participate in the organ donation process. Likewise, opt-in consent refers to the consent process of only those who are registered to participate in organ donation. Currently, the United States has an opt-in system, but studies show that countries with an opt-out system save more lives due to more availability of donated organs. The current opt-in consent policy assumes that individuals are not willing to become organ donors at the time of their death, unless they have documented otherwise through organ donation registration.[28]

Registering to become an organ donor heavily depends on the attitude of the individual; those with a positive outlook might feel a sense of altruism towards organ donation, while others may have a more negative perspective, such as not trusting doctors to work as hard to save the lives of registered organ donors. Some common concerns regarding a presumed consent ("opt-out") system are sociologic fears of a new system, moral objection, sentimentality, and worries of the management of the objection registry for those who do decide to opt-out of donation.[28] Additional concerns exist with views of compromising the freedom of choice to donate,[31] conflicts with extant religious beliefs[32] and the possibility of posthumous violations of bodily integrity.[33] Even though concerns exist, the United States still has a 95 percent organ donation approval rate. This level of nationwide acceptance may foster an environment where moving to a policy of presumed consent may help solve some of the organ shortage problem, where individuals are assumed to be willing organ donors unless they document a desire to "opt-out", which must be respected.[32]

Because of public policies, cultural, infrastructural and other factors, presumed consent or opt-out models do not always translate directly into increased effective rates of donation. The United Kingdom has several different laws and policies for the organ donation process, such as consent of a witness or guardian must be provided to participate in organ donation. This policy was consulted on by Department of Health and Social Care in 2018,[34] and was implemented starting May 20, 2020.[35]

In terms of effective organ donations, in some systems like Australia (14.9 donors per million, 337 donors in 2011), family members are required to give consent or refusal, or may veto a potential recovery even if the donor has consented.[36] Some countries with an opt-out system like Spain (40.2 donors per million inhabitants),[37] Croatia (40.2 donors/million)[37] or Belgium (31.6 donors/million)[37] have high donor rates, however some countries such as Greece (6 donors/million) maintain low donor rates even with this system.[38] The president of the Spanish National Transplant Organisation has acknowledged Spain's legislative approach is likely not the primary reason for the country's success in increasing the donor rates, starting in the 1990s.[39]

Looking to the example of Spain, which has successfully adopted the presumed consent donation system, intensive care units (ICUs) must be equipped with enough doctors to maximize the recognition of potential donors and maintain organs while families are consulted for donation. The characteristic that enables the Spanish presumed consent model to be successful is the resource of transplant coordinators; it is recommended to have at least one at each hospital where opt-out donation is practiced to authorize organ procurement efficiently.[40]

Public views are crucial to the success of opt-out or presumed consent donation systems. In a study done to determine if health policy change to a presumed consent or opt-out system would help to increase donors, an increase of 20 to 30 percent was seen among countries who changed their policies from some type of opt-in system to an opt-out system. Of course, this increase must have a great deal to do with the health policy change, but also may be influenced by other factors that could have impacted donor increases.[41]

Transplant Priority for Willing Donors, also known as the "donor-priority rule", is a newer method and the first to incorporate a "non-medical" criterion into the priority system to encourage higher donation rates in the opt-in system.[42][43] Initially implemented in Israel, it allows an individual in need of an organ to move up the recipient list. Moving up the list is contingent on the individual opting-in prior to their need for an organ donation. The policy applies nonmedical criteria when allowing individuals who have previously registered as an organ donor, or whose family has previously donated an organ, priority over other possible recipients. It must be determined that both recipients have identical medical needs prior to moving a recipient up the list. While incentives like this in the opt-in system do help raise donation rates, they are not as successful in doing so as the opt-out, presumed consent default policies for donation.[36]

Country Policy Year implemented
Argentina opt-out 2005
Austria opt-out
Belarus opt-out 2007[44]
Belgium opt-out
Brazil opt-in
Czech Republic opt-out September 2002[45]
Chile opt-out 2010
Colombia opt-out 2017
Guatemala opt-in February 2024[46]
Israel opt-in
Netherlands opt-out 2020[47]
Spain opt-out 1979
Ukraine opt-in [48]
United Kingdom Wales opt-out December 1, 2015[49]
England May 20, 2020[50]
Scotland March 25, 2021[51]
Northern Ireland June 1, 2023[52]
United States opt-in

Argentina

[edit]

On November 30, 2005, the Congress introduced an opt-out policy on organ donation, where all people over 18 years of age will be organ donors unless they or their family state otherwise. The law was promulgated on December 22, 2005, as "Law 26,066".[53]

On July 4, 2018, the Congress passed a law removing the family requirement, making the organ donor the only person that can block donation. It was promulgated on July 4, 2018, as Law Justina or "Law 27,447".[54]

Brazil

[edit]

A campaign by Sport Club Recife has led to waiting lists for organs in north-east Brazil to drop almost to zero; while according to the Brazilian law the family has the ultimate authority, the issuance of the organ donation card and the ensuing discussions have however eased the process.[55]

Canada

[edit]

In 2001, the Government of Canada announced the formation of the Canadian Council for Donation and Transplantation, whose purpose would be to advise the Conference of Deputy Ministers of Health on activities relating to organ donation and transplantation. The deputy ministers of health for all provinces and territories with the exception of Québec decided to transfer the responsibilities of the Canadian Council for Donation and Transplantation to Canadian Blood Services.[56]

In Québec, an organization called Transplant Québec is responsible for managing all organ donation; Héma-Québec is responsible for tissue donation.[57] Consent for organ donation by an individual is given by either registering with the organ donation registry established by the Chambre des notaires du Québec, signing and affixing the sticker to the back of one's health insurance card, or registering with either Régie de l'assurance maladie du Québec or Registre des consentements au don d'organes et de tissus.[58]

Number of transplants by organ[59]
  1. Kidney (58.5%)
  2. Liver (19.8%)
  3. Lung (11.8%)
  4. Heart (7.30%)
  5. Pancreas (1.10%)
  6. Kidney and Pancreas (1.50%)

In 2017, the majority of transplants completed were kidney transplants.[59] Canadian Blood Services has a program called the kidney paired donation, where transplant candidates are matched with compatible living donors from all over Canada. It also gives individuals an opportunity to be a living donor for an anonymous patient waiting for a transplant. As of December 31, 2017, there were 4,333 patients on the transplant waitlist. In 2017, there were a total of 2,979 transplants, including multi-organ transplants; 242 patients died while on the waitlist. 250 Canadians die on average waiting for transplant organs every year.[60]

Each province has different methods and registries for intent to donate organs or tissues as a deceased donor. In some provinces, such as Newfoundland and Labrador and New Brunswick organ donation registration is completed by completing the "Intent to donate" section when applying or renewing one's provincial medical care.[61][62] In Ontario, one must be 16 years of age to register as an organ and tissue donor and register with ServiceOntario.[63] Alberta requires that a person must be 18 years of age or older and register with the Alberta Organ and Tissue Donation Registry.[64]

Opt-out donation in Canada

[edit]

Nova Scotia, Canada, is the first jurisdiction in North America to introduce an automatic organ donation program unless residents opt out; what the province refers to as deemed consent.[65] The Human Organ and Tissue Act was introduced on April 2, 2019.[66] With the legislation, all people who have been Nova Scotia residents for a minimum of 12 consecutive months, with appropriate decision-making capacity and are over 18 years of age are considered potential donors and will be automatically referred to donation programs if they are determined to be good candidates. In the case of persons under 18 years of age and people without appropriate decision-making capacity, they will only be considered as organ donors if their parent, guardian or decision-maker opts them into the program. The legislation took effect on January 18, 2021.[67]

Chile

[edit]

On January 6, 2010, the "Law 20,413" was promulgated, introducing an opt-out policy on organ donation, where all people over 18 years of age will be organ donors unless they state their negative.[68][69]

Colombia

[edit]

On August 4, 2016, the Congress passed the "Law 1805", which introduced an opt-out policy on organ donation where all people will be organ donors unless they state their negative.[70] The law came into force on February 4, 2017.[71]

Europe

[edit]
Map showing the coverage of three international European organ donation associations:

Within the European Union, organ donation is regulated by member states. As of 2010, 24 European countries have some form of presumed consent (opt-out) system, with the most prominent and limited opt-out systems in Spain, Austria, and Belgium yielding high donor rates.[72] Spain had the highest donor rate in the world, 46.9 per million people in the population, in 2017.[73] This is attributed to multiple factors in the Spanish medical system, including identification and early referral of possible donors, expanding criteria for donors and standardised frameworks for transplantation after circulatory death.[74]

In England, individuals who wish to donate their organs after death can use the Organ Donation Register, a national database. The government of Wales became the first constituent country in the UK to adopt presumed consent in July 2013.[75] The opt-out organ donation scheme in Wales went live on December 1, 2015, and is expected to increase the number of donors by 25%.[76] In 2008, the UK discussed whether to switch to an opt-out system in light of the success in other countries and a severe British organ donor shortfall.[77] In Italy if the deceased neither allowed nor refused donation while alive, relatives will pick the decision on his or her behalf despite a 1999 act that provided for a proper opt-out system.[78] In 2008, the European Parliament overwhelmingly voted for an initiative to introduce an EU organ donor card to foster organ donation in Europe.[79]

Landstuhl Regional Medical Center (LRMC) has become one of the most active organ donor hospitals in all of Germany, which otherwise has one of the lowest organ donation participation rates in the Eurotransplant organ network. LRMC, the largest U.S. military hospital outside the United States, is one of the top hospitals for organ donation in the Rhineland-Palatinate state of Germany, even though it has relatively few beds compared to many German hospitals. According to the German organ transplantation organization, Deutsche Stiftung Organtransplantation (DSO), 34 American military service members who died at LRMC (roughly half of the total number who died there) donated a total of 142 organs between 2005 and 2010. In 2010 alone, 10 of the 12 American service members who died at LRMC were donors, donating a total of 45 organs. Of the 205 hospitals in the DSO's central region—which includes the large cities of Frankfurt and Mainz—only six had more organ donors than LRMC in 2010.[80]

Scotland conforms to the Human Tissue Authority Code of Practice, which grants authority to donate organs, instead of consent of the individual.[24] This helps to avoid conflict of implications and contains several requirements. To participate in organ donation, one must be listed on the Organ Donor Registry (ODR). If the subject is incapable of providing consent, and is not on the ODR, then an acting representative, such as a legal guardian or family member can give legal consent for organ donation of the subject, along with a presiding witness, according to the Human Tissue Authority Code of Practice. Consent or refusal from a spouse, family member, or relative is necessary for a subject is incapable.

Austria participates in the "opt-out" consent process, and have laws that make organ donation the default option at the time of death. In this case, citizens must explicitly "opt out" of organ donation. Yet in countries such as U.S.A. and Germany, people must explicitly "opt in" if they want to donate their organs when they die. In Germany and Switzerland there are Organ Donor Cards available.[81][82]

In May 2017, Ireland began the process of introducing an "opt-out" system for organ donation. Minister for Health, Simon Harris, outlined his expectations to have the Human Tissue Bill passed by the end of 2017. This bill would put in place the system of "presumed consent".[83]

The Mental Capacity Act is another legal policy in place for organ donation in the UK. The act is used by medical professionals to declare a patient's mental capacity. The act claims that medical professionals are to "act in a patient's best interest", when the patient is unable to do so.[24]

India

[edit]

India has a fairly well developed corneal donation programme; however, donation after brain death has been relatively slow to take off. Most of the transplants done in India are living related or unrelated transplants. To curb organ commerce and promote donation after brain death the government enacted a law called "The Transplantation of Human Organs Act" in 1994 that brought about a significant change in the organ donation and transplantation scene in India.[84][85][86][87][88][89][90] Many Indian states have adopted the law and in 2011 further amendment of the law took place.[91][92][93][94][95] Despite the law there have been stray instances of organ trade in India and these have been widely reported in the press. This resulted in the amendment of the law further in 2011. Deceased donation after brain death have slowly started happening in India and 2012 was the best year for the programme.

India
Table 1 – Deceased Organ Donation in India – 2012.
State No. of Deceased Donors Total no. of Organs Retrieved Organ Donation Rate per Million Population
Tamil Nadu 83 252 1.15
Maharashtra 29 68 0.26
Gujarat 18 46 0.30
Karnataka 17 46 0.28
Andhra Pradesh 13 37 0.15
Kerala 12 26 0.36
Delhi-NCR 12 31 0.29
Punjab 12 24 0.43
Total 196 530 0.16

The year 2013 has been the best yet for deceased organ donation in India. A total of 845 organs were retrieved from 310 multi-organ donors resulting in a national organ donation rate of 0.26 per million population(Table 2).

Table 2 – Deceased Organ Donation in India – 2013
State Tamil Nadu Andhra Pradesh Kerala Maharashtra Delhi Gujarat Karnataka Puducherry Total (National)
Donor 131 40 35 35 27 25 18 2 313
* ODR (pmp) 1.80 0.47 1.05 0.31 1.61 0.41 0.29 1.6 0.26
Heart 16 2 6 0 0 1 0 25
Lung 20 2 0 0 0 0 0 22
Liver 118 34 23 23 23 20 16 0 257
Kidney 234 75 59 53 40 54 29 4 548
Total 388 113 88 76 63 74 46 4 852

* ODR (pmp) – Organ Donation Rate (per million population)

In the year 2000 through the efforts of a non-governmental organization called MOHAN Foundation state of Tamil Nadu started an organ sharing network between a few hospitals.[97][98] The MOHAN Foundation also set up similar sharing network in the state of Andhra Pradesh and these two states were at the forefront of deceased donation and transplantation programme for many years.[99][100] As a result, retrieval of 1,033 organs and tissues were facilitated in these two states.[101]

Similar sharing networks came up in the states of Maharashtra and Karnataka; however, the numbers of deceased donation happening in these states were not sufficient to make much impact. In 2008, the Government of Tamil Nadu put together government orders laying down procedures and guidelines for deceased organ donation and transplantation in the state.[102] These brought in almost thirty hospitals in the programme and has resulted in significant increase in the donation rate in the state. With an organ donation rate of 1.15 per million population, Tamil Nadu is the leader in deceased organ donation in the country. The small success of Tamil Nadu model has been possible due to the coming together of both government and private hospitals, non-governmental organizations and the State Health Department. Most of the deceased donation programmes have been developed in southern states of India.[103] The various such programmes are as follows:

  • Andhra Pradesh – Jeevandan programme
  • Karnataka – Zonal Coordination Committee of Karnataka for Transplantation
  • Kerala – Mrithasanjeevani – The Kerala Network for Organ Sharing
  • Maharashtra – Zonal Transplant Coordination Center in Mumbai
  • Rajasthan – Navjeevan – The Rajasthan Network of Organ Sharing
  • Tamil Nadu – Cadaver Transplant Programme

In the year 2012 besides Tamil Nadu other southern states too did deceased donation transplants more frequently. An online organ sharing registry for deceased donation and transplantation is used by the states of Tamil Nadu and Kerala. Both these registries have been developed, implemented and maintained by MOHAN Foundation. However. National Organ and Tissue Transplant Organization (NOTTO) is a National level organization set up under Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India and only official organization.

Organ selling is legally banned in Asia. Numerous studies have documented that organ vendors have a poor quality of life (QOL) following kidney donation. However, a study done by Vemuru reddy et al shows a significant improvement in Quality of life contrary to the earlier belief.[104] Live related renal donors have a significant improvement in the QOL following renal donation using the WHO QOL BREF in a study done at the All India Institute of Medical Sciences from 2006 to 2008. The quality of life of the donor was poor when the graft was lost or the recipient died.[104]

In India, there are six types of life saving organs that can be donated to save the life of a patient. These include Kidneys, Liver, Heart, Lungs, Pancreas and Intestine. Off late, uterus transplant has also been started in India. However, uterus is not a life saving organ as per the Transplantation of Human Organs Act (2011).[105] Recently a scoring system, Seth-Donation of Organs and Tissues (S-DOT) score, has been developed to assess hospitals for best practices in tissue donation and organ donation after brain death.[106]

Iran

[edit]

Only one country, Iran has eliminated the shortage of transplant organs—and only Iran has a working and legal payment system for organ donation. It is also the only country where organ trade is legal. The way their system works is, if a patient does not have a living relative or who are not assigned an organ from a deceased donor, apply to the nonprofit Dialysis and Transplant Patients Association (Datpa). The association establishes potential donors, those donors are assessed by transplant doctors who are not affiliated with the Datpa association. The government gives a compensation of $1,200 to the donors and aid them a year of limited health-insurance. Additionally, working through Datpa, kidney recipients pay donors between $2,300 and $4,500.[107] Importantly, it is illegal for the medical and surgical teams involved or any 'middleman' to receive payment.[108] Charity donations are made to those donors whose recipients are unable to pay. The Iranian system began in 1988 and eliminated the shortage of kidneys by 1999. Within the first year of the establishment of this system, the number of transplants had almost doubled; nearly four-fifths were from living unrelated sources.[108] Nobel Laureate economist Gary Becker and Julio Elias estimated that a payment of $15,000 for living donors would alleviate the shortage of kidneys in the U.S.[107]

Israel

[edit]

Since 2008, signing an organ donor card in Israel has provided a potential medical benefit to the signer. If two patients require an organ donation and have the same medical need, preference will be given to the one that had signed an organ donation card. (This policy was nicknamed "Don't give, don't get".) Organ donation in Israel increased after 2008.[citation needed]

Japan

[edit]

The rate of organ donation in Japan is significantly lower than in Western countries.[109] This is attributed to cultural reasons, some distrust of western medicine, and a controversial organ transplantation in 1968 that provoked a ban on cadaveric organ donation that would last thirty years.[109] Organ donation in Japan is regulated by a 1997 organ transplant law, which defines "brain death" and legalized organ procurement from brain dead donors.

Netherlands

[edit]

The Netherlands sends everyone living in the country a postcard when they turn 18 (and everyone living in the country when the 2020 law came into effect), and one reminder if they do not reply. They may choose to donate, not to donate, to delegate the choice to family, or to name a specific person. If they do not reply to either notice, they are considered a donor by default.[110] A family cannot object unless there is reason to show the person would not have wanted to donate. If a person cannot be found in the national donor registry, because they are travelling from another country or because they are undocumented, their organs are not harvested without family consent. Organs are not harvested from people who die an unnatural death without the approval of the local attorney general.

New Zealand

[edit]
Altruism

New Zealand law allows live donors to participate in altruistic organ donation only. In the five years to 2018, there were 16 cases of liver donation by live donors and 381 cases of kidney donation by live donors.[111] New Zealand has low rates of live donation, which could be due to the fact that it is illegal to pay someone for their organs. The Human Tissue Act 2008 states that trading in human tissue is prohibited, and is punishable by a fine of up to $50,000 or a prison term of up to 1 year.[112] The Compensation for Live Organ Donors Act 2016, which came into force in December 2017, allows live organ donors to be compensated for lost income for up to 12 weeks post-donation.[113]

New Zealand law also allows for organ donation from deceased individuals. In the five years to 2018, organs were taken from 295 deceased individuals.[111] Everyone who applies for a driver's licence in New Zealand indicates whether or not they wish to be a donor if they die in circumstances that would allow for donation.[114] The question is required to be answered for the application to be processed, meaning that the individual must answer yes or no, and does not have the option of leaving it unanswered.[114] However, the answer given on the drivers license does not constitute informed consent, because at the time of drivers license application not all individuals are equipped to make an informed decision regarding whether to be a donor, and it is therefore not the deciding factor in whether donation is carried out or not.[114] It is there to simply give indication of the person's wishes.[114] Family must agree to the procedure for donation to take place.[114][115]

A 2006 bill proposed setting up an organ donation register where people can give informed consent to organ donations and clearly state their legally binding wishes.[116] However, the bill did not pass, and there was condemnation of the bill from some doctors, who said that even if a person had given express consent for organ donation to take place, they would not carry out the procedure in the presence of any disagreement from grieving family members.[117]

The indigenous population of New Zealand also have strong views regarding organ donation. Many Maori people believe organ donation is morally unacceptable due to the cultural need for a dead body to remain fully intact.[118] However, because there is not a universally recognised cultural authority, no one view on organ donation is universally accepted in the Maori population.[118] They are, however, less likely to accept a kidney transplant than other New Zealanders, despite being overrepresented in the population receiving dialysis.[118]

South Korea

[edit]

In South Korea, the 2006 provision of the Organ Transplant Act introduced a monetary incentive equivalent to US$4,500 to the surviving family of brain-death donors; the reward is intended as consolation and compensation for funeral expenses and hospital fees.[119][120]

Sri Lanka

[edit]

Organ donation in Sri Lanka was ratified by the Human Tissue Transplantation Act No. 48 of 1987. Sri Lanka Eye Donation Society, a non-governmental organization established in 1961 has provided over 60,000 corneas for corneal transplantation, for patients in 57 countries. It is one of the major suppliers of human eyes to the world, with a supply of approximately 3,000 corneas per year.[121]

United Kingdom

[edit]

Wales

[edit]
Vaughan Gething, Welsh Government Health Minister, addresses the Kidney Research UK Annual Fellows Day; 2017

Since December 2015, Human Transplantation (Wales) Act 2013 passed by the Welsh Government has enabled an opt-out organ donation register, the first country in the UK to do so. The legislation is 'deemed consent', whereby all citizens are considered to have no objection to becoming a donor, unless they have opted out on this register.[122]

England

[edit]
NHS England Organ Donor Card

The Organ Donation (Deemed Consent) Act 2019 established opt-out organ donation in England, also known as Max and Keira's law, when came into effect in May 2020. It means adults in England will be automatically be considered potential donors unless they chose to opt out or are excluded.[123]

Scotland

[edit]

The Human Tissue (Authorisation) (Scotland) Act 2019 established opt-out organ donation in Scotland in March 2021.[51][124]

Northern Ireland

[edit]

The Organ and Tissue Donation (Deemed Consent) Act (Northern Ireland) 2022 established opt-out organ donation in 2023.[52]

Dependencies

[edit]

In Jersey, the Capacity and Self-Determination (Jersey) Law 2016 established an opt-out register on July 1, 2019.[125][126]

in Guernsey, the Human Tissue and Transplantation (Bailiwick of Guernsey) Law, 2020 established opt-out organ donation in 2023.[127]

In the Isle of Man, the Human Tissue and Organ Donation Act 2021 has provisions to establish opt-out organ donation, which have not been enacted.[128]

United States

[edit]

Over 121,000 people in need of an organ are on the U.S. government waiting list.[129] This crisis within the United States is growing rapidly because on average there are only 30,000 transplants performed each year. More than 8,000 people die each year from lack of a donor organ, an average of 22 people a day.[130][42] Between the years 1988 and 2006 the number of transplants doubled, but the number of patients waiting for an organ grew six times as large.[131]

In the past presumed consent was urged to try to decrease the need for organs. The Uniform Anatomical Gift Act of 1987 was adopted in several states, and allowed medical examiners to determine if organs and tissues of cadavers could be donated. By the 1980s, several states adopted different laws that allowed only certain tissues or organs to be retrieved and donated, some allowed all, and some did not allow any without consent of the family. In 2006 when the UAGA was revised, the idea of presumed consent was abandoned. In the United States today, organ donation is done only with consent of the family or donator themselves.[132]

In most states, residents can register to become organ donors through the Department of Motor Vehicles. The driver's license will serve as a legal donor card for the registered donor. U.S. Residents may also choose to register as organ, eye, and tissue donors through a national registry maintained by Donate Life America. The national website is RegisterMe.org The national registry allows residents to create a login, password, and edit their donation choice by organ. The most common transplants consists of only six (6) organs: heart, lungs, liver, kidney, pancreas, and small intestines. One healthy donor can potentially save up to eight (8) lives through transplants, using the two lungs and two kidneys separately. The most needed organ for transplants overall are kidneys, due to the high rate of hypertension (HTN) or high blood pressure and diabetes which can lead to end-stage renal disease.

According to economist Alex Tabarrok, the shortage of organs has increased the use of so-called expanded criteria organs, or organs that used to be considered unsuitable for transplant.[107] Five patients that received kidney transplants at the University of Maryland School of Medicine developed cancerous or benign tumors which had to be removed. The head surgeon, Dr. Michael Phelan, explained that "the ongoing shortage of organs from deceased donors, and the high risk of dying while waiting for a transplant, prompted five donors and recipients to push ahead with the surgery."[107] Several organizations such as the American Kidney Fund are pushing for opt-out organ donation in the United States.[133]

Donor Leave Laws

[edit]

In addition to their sick and annual leave, federal executive agency employees are entitled to 30 days paid leave for organ donation.[134] Thirty-two states (excluding only Alabama, Connecticut, Florida, Kentucky, Maine, Michigan, Montana, Nebraska, Nevada, New Hampshire, New Jersey, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Vermont, and Wyoming) and the District of Columbia also offer paid leave for state employees.[135] Five states (California, Hawaii, Louisiana, Minnesota, and Oregon) require certain private employers to provide paid leave for employees for organ or bone marrow donation, and seven others (Arkansas, Connecticut, Maine, Nebraska, New York, South Carolina, and West Virginia) either require employers to provide unpaid leave, or encourage employers to provide leave, for organ or bone marrow donation.[135]

A bill in the US House of Representatives, the Living Donor Protection Act (introduced in 2016, then reintroduced in 2017[136]), would amend the Family and Medical Leave Act of 1993 to provide leave under the act for an organ donor. If successful, this new law would permit "eligible employee" organ donors to receive up to 12 work weeks of leave in a 12-month period.[137][138]

Tax incentives

[edit]

Nineteen US states and the District of Columbia provide tax incentives for organ donation.[135] The most generous state tax incentive is Utah's tax credit, which covers up to $10,000 of unreimbursed expenses (travel, lodging, lost wages, and medical expenses) associated with organ or tissue donation.[135] Idaho (up to $5,000 of unreimbursed expenses) and Louisiana (up to $7,500 of 72% of unreimbursed expenses) also provide donor tax credits.[135] Arkansas, the District of Columbia, Louisiana and Pennsylvania provide tax credits to employers for wages paid to employees on leave for organ donation.[135] Thirteen states (Arkansas, Georgia, Iowa, Massachusetts, Mississippi, New Mexico, New York, North Dakota, Ohio, Oklahoma, Rhode Island and Wisconsin) have a tax deduction for up to $10,000 of unreimbursed costs, and Kansas and Virginia offer a tax deduction for up to $5,000 of unreimbursed costs.[135]

States have focused their tax incentives on unreimbursed costs associated with organ donation to ensure compliance with the National Organ Transplant Act of 1984.[139] NOTA prohibits, "any person to knowingly acquire, receive, or otherwise transfer any human organ for valuable consideration for use in human transplantation."[140] However, NOTA exempts, "the expenses of travel, housing, and lost wages incurred by the donor of a human organ in connection with the donation of the organ," from its definition of "valuable consideration".[140]

While offering income tax deductions has been the preferred method of providing tax incentives, some commentators have expressed concern that these incentives provide disproportionate benefits to wealthier donors.[141] Tax credits, on the other hand, are perceived as more equitable since the after tax benefit of the incentive is not tied to the marginal tax rate of the donor.[141]

Additional tax favored approaches have been proposed for organ donation, including providing: tax credits to the families of deceased donors (seeking to encourage consent), refundable tax credits (similar to the earned income credit) to provide greater tax equity among potential donors, and charitable deductions for the donation of blood or organs.[142]

Other financial incentives

[edit]

As stated above, under the National Organ Transplant Act of 1984, granting monetary incentives for organ donation is illegal in the United States.[143] However, there has been some discussion about providing fixed payment for potential live donors. In 1988, regulated paid organ donation was instituted in Iran and, as a result, the renal transplant waiting list was eliminated. Critics of paid organ donation argue that the poor and vulnerable become susceptible to transplant tourism. Travel for transplantation becomes transplant tourism if the movement of organs, donors, recipients or transplant professionals occurs across borders and involves organ trafficking or transplant commercialism. Poor and underserved populations in underdeveloped countries are especially vulnerable to the negative consequences of transplant tourism because they have become a major source of organs for the 'transplant tourists' that can afford to travel and purchase organs.[144]

In 1994 a law was passed in Pennsylvania which proposed to pay $300 for room and board and $3,000 for funeral expenses to an organ donor's family. Developing the program was an eight-year process; it is the first of its kind. Procurement directors and surgeons across the nation await the outcomes of Pennsylvania's program.[145] There have been at least nineteen families that have signed up for the benefit. Due to investigation of the program, however, there has been some concern whether the money collected is being used to assist families.[146] Nevertheless, funeral aids to induce post-mortem organ donation have also received support from experts and the general public, as the incentives present more ethical values, such as honoring the deceased donor or preserving voluntariness, and potentially increase donation willingness.[147][119]

Some organizations, such as the National Kidney Foundation, oppose financial incentives associated with organ donation claiming, "Offering direct or indirect economic benefits in exchange for organ donation is inconsistent with our values as a society."[148] One argument is it will disproportionately affect the poor.[149] The $300–3,000 reward may act as an incentive for poorer individuals, as opposed to the wealthy who may not find the offered incentives significant. The National Kidney Foundation has noted that financial incentives, such as this Pennsylvania statute, diminish human dignity.[148]

Morocco

[edit]

Organ and tissue donation in Morocco is governed by Law No. 16-98, enacted by Dahir No. 1-99-208 on 16 September 1999 (Official Bulletin No. 4726).

To ensure that donations are voluntary, the legislation forbids any financial remuneration and governs the donation, removal, and transplantation of human organs for medical or research purposes.Only close family members may make living contributions; posthumous donations are permitted if the donor gave their approval while still alive or if family members concur after two separate medical professionals have verified the donor's brain death.Any violation of the law, such as the illegal transplantation or organ sale, is penalized by jail time and hefty fines.[150]

Saudi Arabia

[edit]

According to its Human Organ Donation Law, the Kingdom of Saudi Arabia provides legal backing for both living and deceased donors, following Royal Decree published on 1 April 2021 by the Council of Ministers, which took place on 30 March 2021. The law includes provisions that outline the organ donation process; donor consent; medical determination of death; hospital responsibilities; and penalties for non-compliance. Islamic law (Sharia) governs organ donation and prohibits any type of material or financial reward. Public donations from deceased individuals require either the express consent of the deceased or the consent of the next of kin if the deceased is unavailable to provide consent. All public activities, donor lists, and transplant logistics are held by the SCOT (Saudi Center for Organ Transplantation).[151]

Egypt

[edit]

Law No. 5 of 2010, which governs the regulation of organ and human tissue donation and transplantation in Egypt, strictly prohibits any trade in human organs while permitting donation whether from living or deceased donors under stringent legal and medical conditions.

In the case of posthumous donation, it may take place only if the donor has previously given explicit consent before death, and provided that a medical committee formally certifies death in accordance with the established criteria of brain death. However, because of administrative, moral, and religious barriers, the law has not yet been fully implemented. Discussions over the establishment of a national organ donor registry and the efficient enforcement of the law are still going on, and public awareness initiatives have been planned.[152]

Bioethical issues

[edit]

Deontological

[edit]
Lung transplant rejection

Deontological issues are issues about whether a person has an ethical duty or responsibility to take an action. Nearly all scholars and societies around the world agree that voluntarily donating organs to sick people is ethically permissible. Although nearly all scholars encourage organ donation, fewer scholars believe that all people are ethically required to donate their organs after death. Similarly, nearly all religions support voluntary organ donation as a charitable act of great benefit to the community. Certain small faiths such as Jehovah's Witnesses and Shinto are opposed to organ donation based upon religious teachings; for Jehovah's Witnesses, this opposition is absolute whereas there exists increasing flexibility among Shinto scholars. Romani people are also often opposed to organ donation based on prevailing spiritual beliefs and not religious views per se.[153] Issues surrounding patient autonomy, living wills, and guardianship make it nearly impossible for involuntary organ donation to occur.

From the standpoint of deontological ethics, the primary issues surrounding the morality of organ donation are semantic in nature. The debate over the definitions of life, death, human, and body is ongoing. For example, whether or not a brain-dead patient ought to be kept artificially animate to preserve organs for donation is an ongoing problem in clinical bioethics. In addition, some[who?] have argued that organ donation constitutes an act of self-harm, even when an organ is donated willingly.[154]

Further, the use of cloning to produce organs with a genotype identical to the recipient is a controversial topic, especially considering the possibility for an entire person to be brought into being for the express purpose of being destroyed for organ procurement. While the benefit of such a cloned organ would be a zero-percent chance of transplant rejection, the ethical issues involved with creating and killing a clone may outweigh these benefits. However, it may be possible in the future to use cloned stem-cells to grow a new organ without creating a new human being.

A relatively new field of transplantation has reinvigorated the debate. Xenotransplantation, or the transfer of animal (usually pig) organs into human bodies, promises to eliminate many of the ethical issues, while creating many of its own.[155] While xenotransplantation promises to increase the supply of organs considerably, the threat of organ transplant rejection and the risk of xenozoonosis, coupled with general anathema to the idea, decreases the functionality of the technique. Some animal rights groups oppose the sacrifice of an animal for organ donation and have launched campaigns to ban them.[156]

Teleological

[edit]

On teleological or utilitarian grounds, the moral status of "black market organ donation" relies upon the ends, rather than the means.[citation needed] In so far as those who donate organs are often impoverished[citation needed] and those who can afford black market organs are typically well-off,[citation needed] it would appear that there is an imbalance in the trade. In many cases, those in need of organs are put on waiting lists for legal organs for indeterminate lengths of time—many die while still on a waiting list.

Organ donation is fast becoming an important bioethical issue from a social perspective as well. While most first-world nations have a legal system of oversight for organ transplantation, the fact remains that demand far outstrips supply. Consequently, there has arisen a black market trend often referred to as transplant tourism.[citation needed] The issues are weighty and controversial. On the one hand are those who contend that those who can afford to buy organs are exploiting those who are desperate enough to sell their organs. Many suggest this results in a growing inequality of status between the rich and the poor. On the other hand, are those who contend that the desperate should be allowed to sell their organs and that preventing them from doing so is merely contributing to their status as impoverished. Further, those in favor of the trade hold that exploitation is morally preferable to death, and in so far as the choice lies between abstract notions of justice on the one hand and a dying person whose life could be saved on the other hand, the organ trade should be legalized. Conversely, surveys conducted among living donors postoperatively and in a period of five years following the procedure have shown extreme regret in a majority of the donors, who said that given the chance to repeat the procedure, they would not.[157] Additionally, many study participants reported a decided worsening of economic condition following the procedure.[158] These studies looked only at people who sold a kidney in countries where organ sales are already legal.

A consequence of the black market for organs has been a number of cases and suspected cases of organ theft,[159][160] including murder for the purposes of organ theft.[161][162] Proponents of a legal market for organs say that the black-market nature of the current trade allows such tragedies and that regulation of the market could prevent them. Opponents say that such a market would encourage criminals by making it easier for them to claim that their stolen organs were legal.

Legalization of the organ trade carries with it its own sense of justice as well.[163] Continuing black-market trade creates further disparity on the demand side: only the rich can afford such organs. Legalization of the international organ trade could lead to increased supply, lowering prices so that persons outside the wealthiest segments could afford such organs as well.

Exploitation arguments generally come from two main areas:

  • Physical exploitation suggests that the operations in question are quite risky, and, taking place in third-world hospitals or "back-alleys", even more risky. Yet, if the operations in question can be made safe, there is little threat to the donor.
  • Financial exploitation suggests that the donor (especially in the Indian subcontinent and Africa) are not paid enough. Commonly, accounts from persons who have sold organs in both legal and black market circumstances put the prices at between $150 and $5,000, depending on the local laws, supply of ready donors and scope of the transplant operation.[164][165][166] In Chennai, India, where one of the largest black markets for organs is known to exist, studies have placed the average sale price at little over $1,000.[158] Many accounts also exist of donors being postoperatively denied their promised pay.[167]

The New Cannibalism is a phrase coined by anthropologist Nancy Scheper-Hughes in 1998 for an article written for The New Internationalist. Her argument was that the actual exploitation is an ethical failing, a human exploitation; a perception of the poor as organ sources which may be used to extend the lives of the wealthy.[168]

Economic drivers leading to increased donation are not limited to areas such as India and Africa, but also are emerging in the United States. Increasing funeral expenses combined with decreasing real value of investments such as homes and retirement savings which took place in the 2000s have purportedly led to an increase in citizens taking advantage of arrangements where funeral costs are reduced or eliminated.[169]

Brain death versus cardiac death

[edit]
Brain death (Radionuclide Cerebral Blood Flow Scan)

Brain death may result in legal death, but still with the heart beating and with mechanical ventilation, keeping all other vital organs alive and functional for a certain period of time. Given long enough, patients who do not fully die in the complete biological sense, but who are declared brain dead, will usually start to build up toxins and wastes in the body. In this way, the organs can eventually dysfunction due to coagulopathy, fluid or electrolyte and nutrient imbalances, or even fail. Thus, the organs will usually only be sustainable and viable for acceptable use up until a certain length of time. This may depend on factors such as how well the patient is maintained, any comorbidities, the skill of the healthcare teams and the quality their facilities.[170][unreliable medical source?] A major point of contention is whether transplantation should be allowed at all if the patient is not yet fully biologically dead, and if brain death is acceptable, whether the person's whole brain needs to have died, or if the death of a certain part of the brain is enough for legal and ethical and moral purposes.

Most organ donation for organ transplantation is done in the setting of brain death. However, in Japan this is a fraught point, and prospective donors may designate either brain death or cardiac death – see organ transplantation in Japan. In some nations such as Belgium, France, Netherlands, New Zealand, Poland, Portugal, Singapore and Spain, everyone is automatically an organ donor unless they opt out of the system. Elsewhere, consent from family members or next-of-kin is required for organ donation. The non-living donor is kept on ventilator support until the organs have been surgically removed. If a brain-dead individual is not an organ donor, ventilator and drug support is discontinued and cardiac death is allowed to occur.

In the United States, where since the 1980s the Uniform Determination of Death Act has defined death as the irreversible cessation of the function of either the brain or the heart and lungs,[171] the 21st century has seen an order-of-magnitude increase of donation following cardiac death. In 1995, only one out of 100 dead donors in the nation gave their organs following the declaration of cardiac death. That figure grew to almost 11 percent in 2008, according to the Scientific Registry of Transplant Recipients.[171] That increase has provoked ethical concerns about the interpretation of "irreversible" since "patients may still be alive five or even 10 minutes after cardiac arrest because, theoretically, their hearts could be restarted, [and thus are] clearly not dead because their condition was reversible."[171]

Gender inequality

[edit]

The majority of organ donors are women.[172] For example, in the United States, 62% of kidney donors and 53% of liver donors are women. According to an international study published in 2023, which included countries from North America, Europe, and Central Asia, 60-65% of living donors in many countries are women.[173] In the United States, for example, data from the Organ Procurement and Transplantation Network (UNOS) in 2021 showed that women represent about 63% of living organ donors. only 22% of women on dialysis were placed on the kidney transplant waitlist, compared to 30% of men. This disparity persisted even though women had fewer medical comorbidities than men.[174] In India, women constitute 74% of kidney donors and 60.5% of liver donors. Additionally, the number of female organ recipients is conspicuously lower than that of male recipients. In the U.S., 35% of liver recipients and 39% of kidney recipients are women. In India, the figures are 24% and 19% respectively.[175]

A study published in 2022 partially explained these disparities through the higher prevalence of certain diseases in men, immune responses related to childbirth in women, and the mismatch in size between the donor and recipient.[176] These disparities may also be attributed to social and cultural factors, as women are often more willing to support family members, in addition to public health policies that have not given enough attention to addressing these disparities.

Political issues

[edit]

There are also controversial issues regarding how organs are allocated to recipients. For example, some believe that livers should not be given to alcoholics in danger of reversion, while others view alcoholism as a medical condition like diabetes.[citation needed] Faith in the medical system is important to the success of organ donation. Brazil switched to an opt-out system and ultimately had to withdraw it because it further alienated patients who already distrusted the country's medical system.[177] Adequate funding, strong political will to see transplant outcomes improve, and the existence of specialized training, care and facilities also increase donation rates. Expansive legal definitions of death, such as Spain uses, also increase the pool of eligible donors by allowing physicians to declare a patient to be dead at an earlier stage, when the organs are still in good physical condition. Allowing or forbidding payment for organs affects the availability of organs. Generally, where organs cannot be bought or sold, quality and safety are high, but supply is not adequate to the demand. Where organs can be purchased, the supply increases.[178]

Iran adopted a system of paying kidney donors in 1988 and within 11 years it became the only country in the world to clear its waiting list for transplants.

Healthy humans have two kidneys, but can live a healthy life with only one. This enables living donors (inter vivos) to give a kidney to someone who needs it, with little to no long-term risk.[179][180] The most common transplants are to close relatives, but people have given kidneys to other friends. The rarest type of donation is the undirected donation whereby a donor gives a kidney to a stranger. Less than a few hundred of such kidney donations have been performed. In recent years, searching for altruistic donors via the internet has also become a way to find life saving organs. However, internet advertising for organs is a highly controversial practice, as some scholars believe it undermines the traditional list-based allocation system.[181]

Black market organ donation

[edit]

The issue of the black market for organs being legalized has become a widespread debate because if this happens then individuals will most likely be coerced into selling their organs. Additionally, even if there were to become regulations against it most individuals who would be coerced into doing this would most likely be unable to afford legal protection.[182]

The National Transplant Organization of Spain is one of the most successful in the world (Spain has been the world leader in organ donation for decades),[183] but it still cannot meet the demand, as 10% of those needing a transplant die while still on the transplant list.[184] Donations from corpses are anonymous, and a network for communication and transport allows fast extraction and transplant across the country.[citation needed] Spanish law uses an opt-out system, where every person is assumed to be a donor and must consciously opt out.[185] Because family members still can forbid the donation,[185] carefully trained doctors ask the family for permission, making it very similar in practice to the United States system.[186]

In the overwhelming majority of cases, organ donation is not possible for reasons of recipient safety, match failures, or organ condition. Even in Spain, which has the highest organ donation rate in the world, there are only 35.1 actual donors per million people, and there are hundreds of patients on the waiting list.[177] This rate compares to 24.8 per million in Austria, where families are rarely asked to donate organs, and 22.2 per million in France, which—like Spain—has a presumed-consent system.[citation needed]

Prison inmates

[edit]

In the United States, prisoners are not discriminated against as organ recipients and are equally eligible for organ transplants along with the general population. A 1976 U.S. Supreme Court case[187] ruled that withholding health care from prisoners constituted "cruel and unusual punishment". United Network for Organ Sharing, the organization that coordinates available organs with recipients, does not factor a patient's prison status when determining suitability for a transplant.[188][189] An organ transplant and follow-up care can cost the prison system up to one million dollars.[189][190] If a prisoner qualifies, a state may allow compassionate early release to avoid high costs associated with organ transplants.[189] However, an organ transplant may save the prison system substantial costs associated with dialysis and other life-extending treatments required by the prisoner with the failing organ. For example, the estimated cost of a kidney transplant is about $111,000.[191] A prisoner's dialysis treatments are estimated to cost a prison $120,000 per year.[192]

Because donor organs are in short supply, there are more people waiting for a transplant than available organs. When a prisoner receives an organ, there is a high probability that someone else will die waiting for the next available organ. A response to this ethical dilemma states that felons who have a history of violent crime, who have violated others' basic rights, have lost the right to receive an organ transplant, though it is noted that it would be necessary "to reform our justice system to minimize the chance of an innocent person being wrongly convicted of a violent crime and thus being denied an organ transplant".[193]

Prisons typically do not allow inmates to donate organs to anyone but immediate family members. There is no law against prisoner organ donation; however, the transplant community has discouraged use of prisoner's organs since the early 1990s due to concern over prisons' high-risk environment for infectious diseases.[194] Physicians and ethicists also criticize the idea because a prisoner is not able to consent to the procedure in a free and non-coercive environment,[195] especially if given inducements to participate. However, with modern testing advances to more safely rule out infectious disease and by ensuring that there are no incentives offered to participate, some have argued that prisoners can now voluntarily consent to organ donation just as they can now consent to medical procedures in general. With careful safeguards, and with over 2 million prisoners in the U.S., they reason that prisoners can provide a solution for reducing organ shortages in the U.S.[196]

While some have argued that prisoner participation would likely be too low to make a difference, one Arizona program started by former Maricopa County Sheriff Joe Arpaio encourages inmates to voluntarily sign up to donate their heart and other organs.[197] As of 2015, there have been over 16,500 participants.[198][199] Similar initiatives have been started in other US states. In 2013, Utah became the first state to allow prisoners to sign up for organ donation upon death.[200]

Religious viewpoints

[edit]

There are several different religions that have different perspectives. Muslims have a conflicting view regarding the issue, with half believing that it is against the religion. Muslims are commanded to seek medical attention when in need and saving life is a very important factor of the Islamic religion. Christianity is lenient on the topic of organ donation, and believe it is a service of life.[201]

All major religions accept organ donation in at least some form[202] on either utilitarian grounds (i.e., because of its life-saving capabilities) or deontological grounds (e.g., the right of an individual believer to make his or her own decision).[citation needed] Most religions, among them the Roman Catholic Church, support organ donation on the grounds that it constitutes an act of charity and provides a means of saving a life. One religious group, The Jesus Christians, became known as "The Kidney Cult" because more than half its members had donated their kidneys altruistically. Jesus Christians claim altruistic kidney donation is a great way to "Do unto others what they would want you to do unto them."[203] Some religions impose certain restrictions on the types of organs that may be donated and/or on the means by which organs may be harvested and/or transplanted.[204] For example, Jehovah's Witnesses require that organs be drained of any blood due to their interpretation of the Hebrew Bible/Christian Old Testament as prohibiting blood transfusion,[205] and Muslims require that the donor have provided written consent in advance.[205] A few groups disfavor organ transplantation or donation; notably, these include Shinto[206] and the Romani.[205]

Orthodox Judaism considers organ donation obligatory if it will save a life, as long as the donor is considered dead as defined by Jewish law.[205] In both Orthodox Judaism and non-Orthodox Judaism, the majority view holds that organ donation is permitted in the case of irreversible cardiac rhythm cessation. In some cases, rabbinic authorities believe that organ donation may be mandatory, whereas a minority opinion considers any donation of a live organ as forbidden.[207]

Organ shortfall

[edit]
Patient receiving dialysis

The demand for organs significantly surpasses the number of donors everywhere in the world. There are more potential recipients on organ donation waiting lists than organ donors.[208] In particular, due to significant advances in dialysis techniques, patients with end-stage renal disease (ESRD) can survive longer than ever before.[209] Because these patients do not die as quickly as they used to, and as kidney failure increases with the rising age and prevalence of high blood pressure and diabetes in a society, the need especially for kidneys rises every year.[210]

As of March 2014, about 121,600 people in the United States are on the waiting list, although about a third of those patients are inactive and could not receive a donated organ.[211][212] Wait times and success rates for organs differ significantly between organs due to demand and procedure difficulty. As of 2007, three-quarters of patients in need of an organ transplant were waiting for a kidney,[213] and as such kidneys have much longer waiting times. As stated by the Gift of Life Donor Program website, the median patient who ultimately received an organ waited 4 months for a heart or lung—but 18 months for a kidney, and 18–24 months for a pancreas because demand for these organs substantially outstrips supply.[214] An increased prevalence of self-driving cars could exacerbate this problem: In the US, 13% of organ donations come from car crash victims, and autonomous vehicles are projected to reduce the frequency of car crashes.[215]

In Australia, there are 10.8 transplants per million people,[216] about a third of the Spanish rate. The Lions Eye Institute, in Western Australia, houses the Lions Eye Bank. The Bank was established in 1986 and coordinates the collection, processing and distribution of eye tissue for transplantation. The Lions Eye Bank also maintains a waitlist of patients who require corneal graft operations. About 100 corneas are provided by the Bank for transplant each year, but there is still a waiting list for corneas.[217] "To an economist, this is a basic supply-and-demand gap with tragic consequences."[218] Approaches to addressing this shortfall include:

  • Donor registries and "primary consent" laws, to remove the burden of the donation decision from the legal next-of-kin. Illinois adopted a policy of "mandated choice" in 2006, which requires driver's license registrants to answer the question "Do you want to be an organ donor?" Illinois has a registration rate of 60 percent compared to 38 percent nationally.[30] The added cost of adding a question to the registration form is minimal.
  • Monetary incentives for signing up to be a donor. Some economists have advocated going as far as allowing the sale of organs. The New York Times reported that "Gary Becker and Julio Jorge Elias argued in a recent paper[219] that 'monetary incentives would increase the supply of organs for transplant sufficiently to eliminate the very large queues in organ markets, and the suffering and deaths of many of those waiting, without increasing the total cost of transplant surgery by more than 12 percent.'"[218] Iran allows the sale of kidneys and has no waiting list.[220] Organ futures have been proposed to incentivise donation through direct or indirect compensation. The primary argument against such proposals is a moral one; as the article notes, many find such a suggestion repugnant.[218] As the National Kidney Foundation puts it, "Offering direct or indirect economic benefits in exchange for organ donation is inconsistent with our values as a society. Any attempt to assign a monetary value to the human body, or body parts, either arbitrarily, or through market forces, diminishes human dignity."[221]
  • An opt-out system ("dissent solution"), in which a potential donor or his/her relatives must take specific action to be excluded from organ donation, rather than specific action to be included. This model is used in several European countries, such as Austria, which has a registration rate eight times that of Germany, which uses an opt-in system.[30]
  • Social incentive programs, wherein members sign a legal agreement to direct their organs first to other members who are on the transplant waiting list. One historical example of a private organization using this model is LifeSharers, which is free to join and whose members agree to sign a document giving preferred access to their organs.[222] "The proposal [for an organ mutual insurance pool] can be easily summarized: An individual would receive priority for any needed transplant if that individual agrees that his or her organs will be available to other members of the insurance pool in the event of his or her death. … The main purpose [of this proposal] is to increase the supply of transplantable organs in order to save or improve more lives."[223]
  • Encouraging more people in palliative care to become donors. Researcher suggests that 46% of patients in palliative care are eligible, but only 4% are approached to consider eye donation.[224][225]
Blood type (or blood group) is determined, in part, by the ABO blood group antigens present on red blood cells.
  • Technical advances allows the use of donors that were previously rejected. For example, hepatitis C can be knowingly transplanted and treated in the organ recipient.[226]

In hospitals, organ network representatives routinely screen patient records to identify potential donors shortly in advance of their deaths.[227] In many cases, organ-procurement representatives will request screening tests (such as blood typing) or organ-preserving drugs (such as blood pressure drugs) to keep potential donors' organs viable until their suitability for transplants can be determined and family consent (if needed) can be obtained.[227] This practice increases transplant efficiency, as potential donors who are unsuitable due to infection or other causes are removed from consideration before their deaths, and decreases the avoidable loss of organs.[227] It may also benefit families indirectly, as the families of unsuitable donors are not approached to discuss organ donation.[227]

Doctors and patients are sometimes hesitant to accept organs from people who died of brain tumours. However, an analysis of the UK donor registry found no evidence of cancer transmission across more than 750 donations, including people with high-grade tumours. This suggests that it may be safe to increase the use of organs from people who died of a brain tumour, which could help reduce organ shortfall.[228][229]

Distribution

[edit]

The United States has two agencies that govern organ procurement and distribution within the country. The United Network for Organ Sharing and the Organ Procurement and Transplant Network (OPTN) regulate Organ Procurement Organizations (OPO) with regard to procurement and distribution ethics and standards. OPOs are non-profit organizations charged with the evaluation, procurement and allocation of organs within their Designated Service Area (DSA). Once a donor has been evaluated and consent obtained, provisional allocation of organs commences. UNOS developed a computer program that automatically generates donor specific match lists for suitable recipients based on the criteria that the patient was listed with. OPO coordinators enter donor information into the program and run the respective lists. Organ offers to potential recipients are made to transplant centers to make them aware of a potential organ. The surgeon will evaluate the donor information and make a provisional determination of medical suitability to their recipient. Distribution varies slightly between different organs but is essentially very similar. When lists are generated many factors are taken into consideration; these factors include: distance of transplant center from the donor hospital, blood type, medical urgency, wait time, donor size and tissue typing. For heart recipients medical urgency is denoted by a recipients "Status" (Status 1A, 1B and status 2). Lungs are allocated based on a recipients Lung Allocation Score (LAS) that is determined based on the urgency of clinical need as well as the likelihood of benefit from the transplant. Livers are allocated using both a status system and MELD/PELD score (Model for End-stage Liver Disease/Pediatric End-stage Liver Disease). Kidney and pancreas lists are based on location, blood type, Human Leukocyte Antigen (HLA) typing and wait time. When a recipient for a kidney or pancreas has no direct antibodies to the donor HLA the match is said to be a 0 ABDR mismatch or zero antigen mismatch. A zero mismatch organ has a low rate of rejection and allows a recipient to be on lower doses of immunosuppressive drugs. Since zero mismatches have such high graft survival these recipients are afforded priority regardless of location and wait time. UNOS has in place a "Payback" system to balance organs that are sent out of a DSA because of a zero mismatch.

Location of a transplant center with respect to a donor hospital is given priority due to the effects of Cold Ischemic Time (CIT). Once the organ is removed from the donor, blood no longer perfuses through the vessels and begins to starve the cells of oxygen (ischemia). Each organ tolerates different ischemic times. Hearts and lungs need to be transplanted within 4–6 hours from recovery, liver about 8–10 hours and pancreas about 15 hours; kidneys are the most resilient to ischemia.[citation needed] Kidneys packaged on ice can be successfully transplanted 24–36 hours after recovery. Developments in kidney preservation have yielded a device that pumps cold preservation solution through the kidneys vessels to prevent Delayed Graft Function (DGF) due to ischemia. Perfusion devices, often called kidney pumps, can extend graft survival to 36–48 hours post recovery for kidneys. Recently similar devices have been developed for the heart and lungs, in an effort to increase distances procurement teams may travel to recover an organ.

Suicide

[edit]

People who die by suicide have a higher rate of donating organs than average. One reason is lower negative response or refusal rate by the family and relatives, but the explanation for this remains to be clarified.[230] In addition, donation consent is higher than average from people who have died by suicide.[231]

Attempted suicide is a common cause of brain death (3.8%), mainly among young men.[230] Organ donation is more common in this group compared to other causes of death. Brain death may result in legal death, but still with the heart beating, and with mechanical ventilation all other vital organs may be kept completely alive and functional,[170] providing optimal opportunities for organ transplantation.

Controversies

[edit]

In 2008, California transplant surgeon Hootan Roozrokh was charged with dependent adult abuse for prescribing what prosecutors alleged were excessive doses of morphine and sedatives to hasten the death of a man with adrenal leukodystrophy and irreversible brain damage, to procure his organs for transplant.[232] The case brought against Roozrokh was the first criminal case against a transplant surgeon in the US, and resulted in his acquittal. Further, Roozrokh successfully sued for defamation stemming from the incident.[233]

At California's Emanuel Medical Center, neurologist Narges Pazouki said an organ-procurement organization representative pressed her to declare a patient brain-dead before the appropriate tests had been done.[227] In September 1999, eBay blocked an auction for "one functional human kidney" which had reached a highest bid of $5.7 million. Under United States federal laws, eBay was obligated to dismiss the auction for the selling of human organs, which is punishable by up to five years in prison and a $50,000 fine.[234]

On June 27, 2008, Indonesian Sulaiman Damanik, 26, pled guilty in a Singapore court for sale of his kidney to CK Tang's executive chair, Tang Wee Sung, 55, for 150 million rupiah (US$17,000). The Transplant Ethics Committee must approve living donor kidney transplants. Organ trading is banned in Singapore and in many other countries to prevent the exploitation of "poor and socially disadvantaged donors who are unable to make informed choices and suffer potential medical risks."[This quote needs a citation] Toni, 27, the other accused, donated a kidney to an Indonesian patient in March, alleging he was the patient's adopted son, and was paid 186 million rupiah (US$21,000).[citation needed]

Public service announcements

[edit]

Marketing for organ donation must walk a fine line between stressing the need for organ donation and not being too forceful.[235] If the marketing agent is too forceful, then the target of the message will react defensively to the request. According to psychological reactance theory, a person will perceive their freedom threatened and will react to restore the freedom. According to Ashley Anker, the use of transportation theory has a positive effect on target reactions by marketing attempts.[235] When public service announcements use recipient-focused messages, targets were more transported because potential donors experience empathy for the potential recipient.

Awareness about organ donation leads to greater social support for organ donation, in turn leading to greater registration. By starting with promoting college students' awareness of organ donation and moving to increasing social support for organ donation, the more likely people will be to register as organ donors.[236]

The United States Department of Health funded a study by the University of Wisconsin Hospital to increase efforts to increase awareness and the number of registered donors by pursuing members of the university and their family and friends through social media.[25] The results of the study showed a 20% increase in organ donation by creating support and awareness through social media.[25]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Organ donation is the surgical removal of viable organs or tissues from a living or deceased individual for transplantation into another person to treat organ failure or improve physiological function. Living donation typically involves kidneys or portions of the liver, with approximately 6,500 such procedures performed annually , while deceased donation encompasses a broader range including hearts, lungs, livers, kidneys, pancreases, and corneas after legal determination of death. Globally, deceased organ donation reached 45,861 donors in 2023, predominantly from cases, enabling tens of thousands of transplants, though rates vary widely by country due to differences in , laws, and cultural factors. The practice has extended millions of life-years since the first successful transplant in , with one deceased donor potentially benefiting up to eight recipients through solid organ transplants and dozens more via tissues like , corneas, or heart valves. In 2024, the recorded 16,988 deceased donors, contributing to over 48,000 transplants, a 3.3% increase from the prior year, yet persistent shortages result in over 100,000 individuals on waiting lists worldwide, with thousands dying annually before receiving organs. Key achievements include advancements in and preservation techniques that have raised five-year graft survival rates above 80% for kidneys and livers, alongside international registries facilitating cross-border allocation. Consent systems form a core ethical pillar, with most nations employing explicit opt-in models requiring affirmative registration, while a minority have shifted to presumed or frameworks presuming donation unless objected to; empirical studies yield mixed results on , with some analyses showing no significant increase in donation rates from adoption and potential negative spillover effects on . Allocation prioritizes medical urgency, compatibility (e.g., ABO matching), and equity principles like and , but disparities persist, including geographic inequities and lower donation rates among certain demographics. Controversies include organ trafficking, driven by global shortages and prohibitions on compensation, which incentivize illegal markets exploiting vulnerable populations, as documented in peer-reviewed analyses of and non-consensual harvesting. Ethical debates center on versus societal utility, with concerns over family override of donor wishes, in living donation, and religious objections to post-mortem, underscoring tensions between altruism-based systems and incentives that could expand supply without undermining .

Fundamentals

Definition and Types

Organ donation is the surgical removal of a healthy organ or portion of an organ from a living or deceased donor for transplantation into a recipient whose organ has failed or is damaged, aiming to restore function and extend life. This process requires precise medical evaluation to ensure organ viability and compatibility, as mismatched transplants can lead to rejection. Deceased donation, the primary source of organs in most countries, occurs after the donor's legal death and involves two main subtypes: donation after brain death (DBD) and donation after circulatory death (DCD). In DBD, the donor is declared brain dead—irreversible cessation of all brain function, confirmed by neurological criteria and apnea testing—while circulatory and respiratory functions are artificially maintained via mechanical ventilation to preserve organ oxygenation. This allows recovery of multiple solid organs such as the heart, lungs, liver, kidneys, and pancreas, with an average of 3.6 organs retrieved per donor in systems like the UK's. DCD, by contrast, follows irreversible cessation of circulatory and respiratory functions after withdrawal of life-sustaining treatment, typically in controlled settings where organs are procured within minutes to limit ischemic damage; it primarily yields kidneys and livers, averaging 2.9 organs per donor, and expands the donor pool by including non-brain-dead patients. Living donation involves a healthy individual voluntarily donating a renewable or regenerable organ segment while remaining alive, most commonly one or a portion of the liver, which can regenerate in both donor and recipient. Other living donations include lobes, segments of or intestine, though these carry higher s and are less frequent. Living donations are classified as directed, where the organ goes to a specified recipient such as a member, or non-directed (altruistic), allocated anonymously via waitlists; paired exchanges enable incompatible donor-recipient pairs to swap organs through chains. Living donors undergo rigorous screening to minimize complications, with kidney donation mortality risk estimated at 0.03% and liver donation at higher rates due to procedural complexity.

Organs and Tissues Involved

Organ donation typically involves the procurement of solid organs and various tissues from deceased or living donors for transplantation into recipients with organ failure or tissue damage. Solid organs suitable for donation include the heart, which restores cardiac function in end-stage heart failure; the lungs, often donated as a pair to treat conditions like chronic obstructive pulmonary disease or cystic fibrosis; kidneys, the most frequently transplanted organ due to high demand from chronic kidney disease; the liver, which can be whole or split for multiple recipients; the pancreas, used primarily for diabetes management in conjunction with kidney transplants; and the small intestine, for patients with intestinal failure. Tissues donated encompass corneas, which restore vision in cases of corneal blindness and account for the majority of tissue transplants; , employed in treatment and coverage; and connective tissues such as tendons, ligaments, and , utilized for orthopedic repairs; heart valves, for congenital defects or valve ; and vascular components like veins and arteries, applied in bypass surgeries. Less common donations include segments of the for hearing restoration and nerves for peripheral nerve repair, though these are limited by preservation challenges and lower demand compared to corneas or musculoskeletal tissues. A single deceased donor can yield up to eight solid organs and numerous tissues, potentially benefiting over 75 recipients, depending on donor viability and logistical factors. Living donors primarily contribute kidneys or liver lobes, regenerating sufficiently post-donation, while tissue donations from living sources are rarer but possible for skin or .

Medical Processes

Donor Assessment and Compatibility

Donor assessment for deceased organ donation begins with confirmation of using neurologic criteria (DNC), defined as the irreversible cessation of all functions of the entire , including the , as established by clinical examination and, where necessary, ancillary tests such as cerebral blood flow scans to demonstrate absence of intracranial blood flow. Prerequisites for DNC include known etiology of , exclusion of confounding factors like sedatives or , and absence of reflexes, with two examinations by qualified physicians separated by observation periods—typically six hours for adults. Following death determination, evaluation proceeds to review for exclusion criteria such as active malignancies (except certain skin or primary cancers), uncontrolled infections, or hemodynamic instability, alongside laboratory tests for transmissible diseases including , and C, and via and testing. UNOS, through the OPTN, applies no specific exclusion criteria to deceased donors who died from drug overdose; these donors are evaluated under general medical suitability and infectious disease screening criteria as with others. Organs from overdose donors are eligible for transplantation if they meet viability standards and screening requirements. Donors with a history of non-medical injection drug use may be classified as "increased risk" for transmitting HIV, hepatitis B, or hepatitis C per Public Health Service (PHS) guidelines, requiring special informed consent from recipients. Overdose deaths have become a significant and growing source of donated organs in the US, with good transplant outcomes reported. Organ-specific assessments gauge viability, for instance, for cardiac function or for lung evaluation, aiming to maximize graft utilization while minimizing transmission risks. For living donors, assessment is more rigorous to protect donor safety, requiring candidates to be at least 18 years old, in excellent physical health without comorbidities like , , or renal insufficiency, and undergo comprehensive evaluations including medical history, physical exam, imaging (e.g., CT angiography for liver donors), renal function tests, and psychosocial screening to ensure and low psychological risk. Ethical guidelines emphasize documenting long-term outcomes, with annual reviews tracking morbidity, mortality, and satisfaction rates post-donation. Conditions disqualifying donors include active cancer, chronic infections, or psychiatric instability, as these elevate perioperative risks or impair future health. Compatibility matching prioritizes ABO blood group congruence to avert hyperacute rejection, where incompatible antigens trigger immediate antibody-mediated damage; for example, O donors are universal for all recipients, while AB recipients accept from any group. (HLA) typing follows, assessing matches at key loci (A, B, DR for kidneys) to lessen acute and chronic rejection; zero-mismatch transplants yield superior graft survival, though partial mismatches are common due to donor shortages. A critical crossmatch test detects recipient antibodies against donor cells via or , with positive results indicating high immunologic risk and often contraindicating direct donation unless desensitization protocols are employed. (PRA) levels further stratify sensitized recipients, influencing allocation priority in paired exchange programs to optimize matches. Additional factors like donor-recipient size, age, and sex influence outcomes, with algorithms in systems like UNOS integrating these for equitable distribution.

Procurement, Preservation, and Transplantation

Organ procurement from deceased donors typically occurs after confirmation of brain death or circulatory death, followed by family consent or prior registration, and thorough medical evaluation to assess organ viability. The process involves transporting the donor to an operating room where specialized surgical teams, coordinated by organ procurement organizations (OPOs), perform the recovery under sterile conditions akin to standard surgeries. Incisions are made—often a sternotomy for thoracic organs and a laparotomy for abdominal ones—and organs are dissected while maintaining hemodynamic stability through continued ventilation and perfusion until removal. To minimize warm ischemia time, organs are sequentially procured, starting with hearts and lungs (due to their short viability windows), followed by livers, pancreases, intestines, and kidneys; vascular structures are cannulated and flushed in situ with cold preservation solutions like University of Wisconsin or histidine-tryptophan-ketoglutarate to rapidly cool and protect against hypoxic damage. Post-procurement, organs are preserved primarily through static cold storage (), the clinical standard since the 1980s, wherein they are submerged in ice-cold (0–4°C) preservation solutions within sterile containers to slow metabolic activity and reduce ischemic injury. Viability timelines vary by organ: hearts and lungs remain suitable for transplantation 4–6 hours after , livers up to 12 hours, and kidneys 24–36 hours under optimal SCS conditions, though these limits shorten with donor factors like age or . Emerging machine techniques—hypothermic (pulsatile or pressure-controlled flow at ) or normothermic (body-temperature oxygenated )—extend preservation times, enable viability assessment via biomarkers or function tests, and mitigate , particularly for marginal donors; clinical trials show reduced delayed graft function in kidneys and primary non-function in livers compared to SCS. Transportation occurs via dedicated flights or ground vehicles to matched recipients, prioritized by national allocation systems like the (UNOS) in the U.S., ensuring compatibility in , size, and urgency. Transplantation surgery at the recipient center involves explanting the failed organ, implanting the donor organ through vascular anastomoses (e.g., aorta-to-iliac for kidneys) and ductal connections (e.g., ureter-to-bladder or bile duct-to-intestine for livers), followed by reperfusion and ; operative times range from 3–6 hours for kidneys to 8–12 hours for multivisceral procedures, with intraoperative monitoring for immediate function. Success hinges on minimizing total cold ischemia time, as prolonged durations correlate with higher rates of acute rejection and graft loss.

Outcomes and Survival Rates

One-year patient survival rates for transplants from deceased donors exceed 94%, with five-year graft survival rates reaching 82.2% for younger recipients (aged 18-34 years) and 66.1% for older groups, outperforming dialysis where five-year survival falls below 50%. Living donor transplants yield superior outcomes, with five-year graft survival at 90.0% in younger recipients, and overall long-term mortality 48-82% lower than remaining on dialysis after the first year, during which survival is comparable (94% for transplants versus 95% for dialysis). For donors, benefits include saving a recipient's life, shorter wait times for the recipient, and positive emotional impacts reported by many, though risks are low but include surgical complications such as infection or bleeding, and slight long-term increases in risks for high blood pressure or kidney issues, with lifelong monitoring recommended. Liver transplants demonstrate one-year patient survival around 90-95%, with five-year rates approximately 75-80%, though multi-organ combinations like -liver show elevated adjusted hazard ratios for mortality (1.94) relative to single transplants. Heart transplants achieve one-year survival near 90%, with improvements in timely access (57.4% transplanted within one year in recent ) contributing to stable or rising long-term outcomes, including 100% 90-day survival in select high-performing centers. transplants have one-year survival at 88.5% for recipients in 2022, remaining stable over the past decade despite a 10.4% increase in procedure volume from 2023 to 2024, though five-year rates hover around 50% due to chronic rejection risks.
Organ1-Year Patient Survival5-Year Graft/Patient SurvivalKey Factors
(Deceased Donor)~94-95%~66-82%Superior to dialysis long-term; age-dependent decline.
(Living Donor)~95-97%~80-90%Lower rejection; better for younger recipients.
Liver~90-95%~75-80%Improved volume but higher risk in multi-organ cases.
Heart~90%~75%Timely access enhances outcomes.
88.5%~50%Stable short-term; rejection limits .
Outcomes vary by donor type, recipient age, comorbidities, and immunological matching, with deceased donor grafts facing higher rejection rates (e.g., via acute cellular or antibody-mediated mechanisms) than living donors, though overall U.S. transplant volumes rose to over 48,000 in 2024, reflecting procedural advancements. Pre-transplant dialysis duration inversely correlates with post-transplant survival, underscoring early referral benefits.

History

Early Practices and Milestones

The concept of organ transplantation appears in ancient legends across cultures, including Roman, Greek, Indian, Chinese, and Egyptian accounts of gods or healers replacing organs with those from cadavers or animals, though no confirms these as actual practices. Early documented tissue transplantation efforts focused on skin grafts; the from circa 1550 BC describes grafting for burns, while Indian surgeon around 600 BC reportedly performed full-thickness skin grafts. A legendary 4th-century AD account, "The Miracle of the Black Leg," attributes limb transplantation to saints Cosmas and Damian, but it remains apocryphal without verifiable outcomes. In the modern era, initial successes involved tissues rather than solid organs. In 1869, French surgeon Jacques-Louis Reverdin achieved the first documented successful skin transplant via epidermic grafting, marking a foundational advancement in transplant techniques. Ophthalmological progress followed with the first successful full-thickness corneal transplant on December 7, 1905, performed by Eduard Zirm in (then , now ); he transplanted tissue from an 11-year-old donor's eye into a 45-year-old laborer blinded by lime burns, with the graft remaining clear long-term despite lacking . These procedures relied on living or recently deceased donors but faced high rejection rates without understanding immune responses. Attempts at solid organ transplantation began in the early amid experimental vascular developed by around 1902–1912, enabling organ perfusion studies in animals. The first human allograft occurred on April 3, 1933, when Ukrainian surgeon Yurii Voronoy transplanted a from a deceased donor into a patient with acute ; the recipient survived only two days due to rejection and incompatibility. Further efforts in the and early , such as Richard Lawler's 1950 cadaveric transplant in yielding brief function, underscored persistent immunological barriers. The breakthrough came on December 23, 1954, when Joseph Murray and colleagues at Peter Bent Brigham Hospital in successfully transplanted a between identical twins Ronald and Richard Herrick, achieving indefinite graft survival without due to genetic matching; this remains the first verified long-term human organ transplant success.

Modern Developments (20th-21st Centuries)

The first successful human transplant took place on December 23, 1954, at Peter Bent Brigham Hospital in , where surgeon Joseph E. Murray and colleagues transplanted a from identical twin donor Ronald Herrick to recipient Richard Herrick, achieving long-term function without immunosuppressive therapy due to the genetic match. This milestone, awarded Murray the in or in 1990, marked the onset of viable solid organ transplantation, though early procedures faced high rejection rates without effective . Subsequent transplants between non-identical donors in the late 1950s and early 1960s incorporated and corticosteroids, improving short-term survival but still limited by acute rejection. Pivotal advancements followed with the first human heart transplant on December 3, 1967, performed by at in , ; the recipient, , survived 18 days despite postoperative , demonstrating surgical feasibility amid ethical debates over donor criteria. Concurrently, the Harvard Ad Hoc Committee's 1968 report defined "irreversible coma" via absent reflexes, apnea, and electrocerebral silence as a new standard for death, enabling procurement from ventilator-supported donors and distinguishing neurological from cardiopulmonary cessation. This framework, adopted widely by 1970s legislation like the 1981 in the U.S., expanded deceased donation pools but sparked ongoing scrutiny over diagnostic reliability and equivalence to traditional death. The late 1970s introduction of cyclosporine, a inhibitor discovered from fungal extracts, transformed outcomes by selectively suppressing T-cell activation and reducing rejection; clinical trials from 1978 onward yielded one-year graft survival rates exceeding 80%, compared to under 50% previously, spurring exponential growth in heart, liver, and other transplants. By the 1980s, organizations proliferated, with the U.S. establishing the in 1984 to allocate via medical urgency and compatibility, formalizing equitable distribution amid rising waitlists. In the , techniques like hypothermic machine perfusion—reviving marginal organs via controlled cooling and oxygenation—have increased utilization of extended-criteria donors, with studies showing 20-30% viability gains for and livers previously discarded. Paired exchange programs, initiated prominently in the U.S. in 2005, facilitated over 100 incompatible pairs annually by 2020 through chain donations, addressing ABO and HLA barriers. Donation after circulatory death surged, comprising 20-25% of U.S. deceased donors by 2022, alongside record volumes of 42,887 transplants that year, driven by expanded criteria yet persistent shortages exceeding 100,000 waitlisted patients. Emerging trials, using gene-edited porcine organs, achieved human survivals of months by 2024, though immunological and infectious risks remain unresolved. Opt-in systems require prospective donors to explicitly register their , typically through government registries, notations, or donor cards, ensuring that only those who affirmatively agree have their organs procured after . In contrast, systems, or presumed models, default to assuming from all adults unless they actively register an objection, shifting the burden from to deliberate refusal. These models differ fundamentally in their treatment of individual choice: opt-in prioritizes expressed willingness, while leverages behavioral defaults to presume in the absence of objection. Globally, systems are adopted in countries such as , , , and , where deceased donor rates per million population (pmp) often exceed those in opt-in nations like the and . For instance, achieved 49.4 deceased donors pmp in 2023, the highest in , followed by at 36.8 pmp, both under frameworks. A 2014 panel study of 48 countries found policies correlated with higher donation and transplant rates, estimating an average increase of 5.66-11.64 donors pmp compared to opt-in systems. Systematic reviews similarly associate presumed consent with donation rate uplifts of 20-30% in some analyses, attributing this to the reducing inertia against donation. However, causal evidence remains contested, as opt-out countries' higher rates often coincide with robust , public , and procurement coordination rather than consent policy alone. Spain's success, for example, stems primarily from its National Transplant Organization's (ONT) emphasis on family engagement and hospital protocols, not merely presumed , with family rates around 10-15% even in opt-out settings. Longitudinal studies and meta-analyses indicate limited or no isolated impact from shifts; a 2021 analysis concluded opt-out changes do not consistently boost rates when confounders like healthcare systems are controlled. In , the 2020 transition to "soft" —where families retain power—yielded a consent rate decline from 67% in 2019 to 61% in 2023, failing to elevate donations as projected and highlighting implementation challenges. Critics argue undermines bodily by equating non-objection with , potentially eroding trust in medical institutions and fostering perceptions of state overreach over personal remains. Ethical concerns include the risk of presuming from those unaware of the or culturally averse to , with surveys showing can diminish perceived and prompt family overrides in 20-50% of cases across systems. Proponents counter that defaults reflect majority preferences—polls indicate 70-90% support in principle—and save lives without coercion, as pairs with easy opt-out mechanisms. Yet, empirical gaps persist: no randomized trials exist, and cross-jurisdictional comparisons confound with cultural factors, suggesting 's benefits are marginal without complementary reforms like mandatory or enhanced registries. In practice, most regimes operate as "soft" models, consulting families regardless, blurring distinctions and tempering rate advantages.

Global Variations and Case Studies

Organ donation practices and rates exhibit significant global disparities, influenced by legal frameworks, cultural attitudes, healthcare infrastructure, and economic factors. In 2023, worldwide deceased organ donors totaled approximately 45,861, covering about 75% of the global population, yet per million population (pmp) rates ranged from over 40 in leading countries to under 5 in others. High-performing nations often feature coordinated networks and presumed elements, while lower rates correlate with opt-in systems, religious reservations, or weak enforcement against illegal alternatives. Living donation varies similarly, with some regions relying heavily on familial or incentivized unrelated donors to bridge deceased shortages.
CountryDeceased Donors pmp (Recent Data)Key System Features
47 (2022)Soft opt-out with national coordination
~42 (2023 est.)Opt-in, registry-driven
Low deceased; high livingRegulated paid living donation
~0.5-1 (deceased)Opt-in; trafficking prevalent despite bans
Spain exemplifies effective policy implementation, achieving the world's highest deceased donor rates through the Spanish National Transplant Organization (ONT), established in 1989, which emphasizes professional training, hospital procurement coordinators, and family counseling despite a soft system where relatives retain veto power. This model has sustained over 40 donors pmp for decades, attributing success to universal ICU screening for potential donors and public campaigns fostering trust, rather than type alone. In 2023, performed over 6,000 transplants, demonstrating scalable infrastructure that other nations, like the , have partially adopted via similar coordinator programs. Iran's approach addresses shortages via a government-regulated compensated living donation program initiated in 1988, eliminating deceased waitlists by 1999 through payments of about $1,400 plus one-year medical to unrelated donors, funded by charity and state mechanisms without formal brokers. This system has facilitated over 35,000 transplants by 2019, prioritizing domestic patients and banning foreign recipients to curb tourism, though critics note potential risks for poor donors and incomplete data on long-term outcomes. shows it reduces dialysis dependency but raises ethical concerns over , with no equivalent for other organs. In , organ donation lags due to cultural taboos, inadequate deceased procurement (under 1 pmp), and persistent illegal trafficking exploiting impoverished donors, often via cross-border networks with , where victims receive minimal compensation while intermediaries profit. The Transplantation of Human Organs Act (2008 amendments) mandates brain-death certification and bans commercial dealings, yet enforcement gaps enable private clinics to conduct thousands of illicit procedures annually, as evidenced by police raids uncovering syndicates. A 2024 analysis highlights as a causal driver, with trafficked kidneys sold for 5,0005,000-10,000 abroad versus $1,000 to donors, underscoring failures in legal deterrence and public awareness.

Incentives, Regulations, and Reforms

In the United States, the National Organ Transplant Act (NOTA) of 1984 prohibits the sale or purchase of organs for transplantation, establishing a framework for altruistic donation while authorizing the Organ Procurement and Transplantation Network (OPTN) to oversee allocation and standards. Regulations enforced by the under the 1998 Final Rule require OPTN to develop policies ensuring equitable distribution, data reporting, and prohibition of incentives that could commodify organs, with violations punishable by fines or loss of Medicare funding for transplant centers. In , the European Union's Directive 2010/53/EU sets minimum standards for quality and safety in organ donation and transplantation, mandating traceability, consent verification, and prevention of organ trafficking, while adhering to the Council of Europe's Oviedo Convention, which emphasizes free and without financial inducements. Current incentives primarily consist of non-monetary measures to encourage donation without violating anti-trafficking laws. In the , programs reimburse funeral expenses for deceased donors' families up to $5,000 in some states and offer priority listing for future transplants to living donors' relatives, though empirical evidence on their impact remains limited due to small sample sizes and confounding factors like consent rates. Surveys indicate that approximately 48% of support some form of compensation, such as tax credits or benefits, potentially increasing willingness to donate, but ethical concerns persist regarding of vulnerable populations. Iran's regulated compensation for living donors, operational since 1988, provides government payments of about $1,200–$4,200 plus one year of health coverage, which has eliminated its kidney transplant waiting list but faces criticism for inadequate long-term donor follow-up, potential exploitation of the poor, and unverified claims of eliminating shortages entirely. Reforms aimed at boosting supply focus on removing financial disincentives and testing controlled incentives. A federal rule expanded reimbursement for living donors' lost wages, travel, and childcare, leading to observed increases in living donations in states with similar prior policies, as such measures address verifiable economic barriers without direct payment for organs. Proposed like the End Deaths Act seeks to provide up to $50,000 in tax credits over five years for nondirected living donors, with modeling suggesting net healthcare savings of $38,000–$169,000 per donor through reduced dialysis costs, though real-world implementation risks include market distortions if not tightly regulated. Shifts to presumed consent () systems, as in the UK's reform and 's longstanding model, show inconsistent results: achieves 40+ donors per million population annually through robust infrastructure rather than alone, while cross-country analyses find no significant average increase in deceased donation rates post- (e.g., 20.3 vs. 15.4 per million in vs. opt-in nations) and potential crowding out of living donations. Recent scrutiny of organizations () has prompted reform calls, including performance-based contracting, after evidence of inflated metrics and conflicts of interest that hinder recovery rates.

Ethical Debates

Definitions of Death

The determination of is central to organ donation, as organs must be procured from deceased donors under the dead donor rule, which prohibits retrieving vital organs from living individuals to avoid causing . Traditionally, was defined by the irreversible cessation of cardiopulmonary functions—spontaneous and circulation—verifiable after a period without , typically minutes to hours post-arrest. This definition persists for donation after circulatory (DCD), where is declared following withdrawal of life-sustaining treatment, confirmed by absence of pulse, respirations, and often apnea testing, with a mandatory observation period (e.g., 2-5 minutes in U.S. protocols) to ensure irreversibility. Advances in in the mid-20th century decoupled cardiopulmonary failure from brain function, prompting redefinition. In 1968, the Harvard Committee's criteria for "irreversible coma" established as: complete unresponsiveness, apnea, absence of reflexes (including ), and an isoelectric electroencephalogram, observed over 24 hours without or drug effects. These criteria, influenced by rising ventilator use and organ transplant needs post-1967 first heart transplant, equated total brain failure with death despite ongoing somatic functions like heartbeat. The 1981 Uniform Determination of Death Act (UDDA), adopted in 45 U.S. states and influencing international standards, formalized death as either irreversible cessation of circulatory/respiratory functions or of all , including the , per accepted medical standards. determination requires two exams by qualified physicians, including , apnea (PaCO2 >60 mmHg), absent brainstem reflexes, and often confirmatory tests like or nuclear scans showing no blood flow. For donation after (DBD), organs are procured while the body is ventilated, preserving viability. Controversies persist, as lacks universal biological consensus; critics, including some neurologists and ethicists, argue it conflates severe neurological injury with death, given integrated bodily functions (e.g., in brain-dead women) and rare recoveries misdiagnosed as . Empirical data show diagnostic errors in <1% of cases with strict protocols, but variability in state laws and incomplete testing in some jurisdictions raise reliability concerns. Religious objections, such as from Orthodox viewing only cardiopulmonary cessation as death, and philosophical debates over the dead donor rule's circularity—defining death partly to enable donation—underscore tensions between utilitarian organ procurement and causal definitions of death rooted in organismal integration. These issues have prompted calls to revise the UDDA for consistency, though changes risk reducing donations without clearer alternatives.

Bodily Autonomy and Property Rights

Bodily autonomy in organ donation refers to the principle that individuals retain sovereign control over their physical integrity, including the decision to donate organs during life or after death. This right, rooted in respect for persons, precludes non-consensual harvesting, even when organs could save lives, as enforced removal constitutes a violation akin to battery. In living donation contexts, autonomy demands rigorous assessment of donor comprehension of risks—such as surgical complications or long-term health impacts—while guarding against undue influence from recipients or family. Presumed consent systems, adopted in countries like since 1979 and the from 2020, presume donation authorization absent explicit , aiming to boost supply amid global shortages where over 100,000 patients await transplants in the U.S. alone as of 2023. Critics contend this erodes by shifting the burden to refusal, potentially exploiting inertia or ignorance; empirical data from opt-out jurisdictions show higher donation rates (e.g., 's 48 donors per million population in 2022 versus 36 in opt-in U.S.), but surveys indicate many non-donors remain unaware of default status, raising concerns. Proponents counter that explicit opt-in underemphasizes communal , yet first-principles analysis prioritizes affirmative volition to prevent state presumption over individual sovereignty. Property rights frameworks extend to organs, positing that competent adults may alienate body parts via sale or , as articulated in where derives from personal sovereignty rather than communal claim. Advocates argue regulated markets—unlike altruistic models limited to 20-30% willingness in surveys—could eliminate waiting-list deaths (e.g., 17 daily in the U.S. per 2023 OPTN data) by commodifying surplus organs like kidneys, with Iran's vendor program since 1988 yielding 1,500-2,000 paid transplants annually despite regulatory flaws. Opponents invoke , asserting organs defy proprietary transfer due to inseparability from , as reflected in U.S. law's quasi-property status for cadavers since the , prohibiting commerce to avert exploitation of the vulnerable. This tension persists, with proposals for futures markets or incentives tested in pilots like Pennsylvania's donor priority registry, balancing rights against utilitarian imperatives without empirical resolution on net welfare gains.

Balancing Utilitarian Gains Against Individual Rights

Proponents of utilitarian approaches in organ donation policy emphasize the potential to maximize overall welfare by expanding the donor pool, thereby reducing mortality on transplant waiting lists. , where explicit opt-in predominates, approximately 5,688 patients died while awaiting transplants in recent years, underscoring the acute shortage. Policies such as presumed (opt-out systems) have been credited with higher donation rates in adopting countries, with some analyses estimating modest increases in transplants and life-years saved. However, rigorous evidence on causation remains inconclusive, as higher rates in opt-out jurisdictions often correlate with factors like public awareness campaigns, healthcare infrastructure, and cultural attitudes toward donation rather than the consent mechanism alone. Critics contend that utilitarian gains cannot justify encroachments on individual rights, particularly the principle of , which entails sovereign control over one's body, extending to decisions about post-mortem use. Presumed consent presumes a default willingness to donate absent explicit objection, potentially leading to the harvesting of organs from individuals who neither ed nor actively refused, thereby violating deontological protections against non-consensual bodily invasion. This framework risks treating silence as assent, undermining the ethical requirement for affirmative, informed choice and conflating individual agency with state-imposed defaults.85062-9/fulltext) From a rights-based perspective, organs represent an extension of and , where even post-death extraction without permission constitutes a form of expropriation, regardless of aggregate societal benefits. Efforts to balance these tensions include mandated choice models, which require individuals to actively declare their preferences during life (e.g., via renewal or tax filings), thereby respecting while prompting reflection on . Such systems avoid the presumptive overreach of while addressing in opt-in regimes, potentially increasing explicit consents without coercing the unwilling. Empirical support for this approach derives from , where structured prompts elevate participation in prosocial decisions without eroding voluntary intent. Philosophically, this aligns with by upholding respect for persons over unverified utilitarian projections, as the moral weight of erroneous organ retrievals—irreversible violations of —outweighs probabilistic gains in transplants. Despite these alternatives, policy shifts toward persist in some regions, often driven by consequentialist rationales that downplay risks, highlighting ongoing tensions between empirical outcomes and foundational .

Economic Aspects

Costs, Funding, and Market Dynamics

The costs of organ transplantation vary significantly by organ type, recipient condition, and geographic location, encompassing procurement, surgical procedures, hospitalization, initial immunosuppression, and follow-up care. In the United States, a kidney transplant averages $442,500 as of 2020 data, with charges for the transplant admission representing the largest component. Heart transplants exceed $1.3 million on average, while liver transplants typically range from $500,000 to over $800,000, driven by operative complexity and perioperative complications. These figures exclude long-term immunosuppression costs, which add $2,000 to $30,000 annually per patient depending on regimen and generics availability. Globally, costs are lower in countries with subsidized systems or lower labor expenses; for instance, liver transplants in India or Turkey range from $50,000 to $60,000, though quality and post-transplant outcomes may differ due to infrastructural variances. Funding for relies heavily on public insurance, private payers, and philanthropic support, with governments absorbing substantial portions in high-income nations. In the , Medicare covers transplants for end-stage renal disease patients under Parts A and B, including inpatient services, physician fees, and select immunosuppressants, though beneficiaries face 20% coinsurance on Part B claims after deductibles. Medicare also reimburses organizations for acquisition costs—such as transportation and preservation—totaling $1.6 billion in 2016 for its share alone, though under-reimbursement pressures centers amid rising fly-out expenses, which surged 77% in some analyses. Private insurers cover non- transplants variably, often with pre-authorization and lifetime caps, while uninsured patients access grants up to $500 for living expenses via programs like the American Transplant Foundation's assistance. Internationally, funding disparities exacerbate access; in , limited public expenditure renders transplants costing over $10,000 unaffordable for most, relying on out-of-pocket payments or aid. The global transplantation market, valued at $10.96 billion in 2024, reflects expanding volume but underscores funding strains as demand outpaces supply. Market dynamics in organ donation stem from a regulated, non-commercial system prohibiting donor compensation, which enforces altruistic supply and generates chronic shortages despite technological advances. This framework, operationalized through entities like the (UNOS) in the , yields fixed supply unresponsive to signals, resulting in waiting lists exceeding patients amid 48,149 transplants in —a 3.3% increase yet insufficient to clear backlogs. Economic analyses liken the to a zero-price equilibrium, where absent incentives, supply fails to match rising from aging populations and chronic diseases, leading to rationing by medical urgency rather than . inefficiencies compound costs; high-donor-risk indices elevate per-transplant expenses by up to $22,000 post-operatively, while global disparities show higher-income nations dominating activity due to funded infrastructures. Proposals for regulated incentives aim to address this disequilibrium, though ethical and regulatory barriers persist, maintaining a system where shortages drive mortality without price-mediated allocation.

Efficacy of Financial Incentives

Financial incentives for organ donation, particularly for living kidney donors, have been implemented in Iran since 1988 through a regulated system of compensated living unrelated donations, which has demonstrably increased the supply of kidneys to the point of eliminating official waiting lists by matching donors and recipients via government oversight and payments typically ranging from $1,200 to $4,500 per donor. This model has facilitated over 30,000 kidney transplants by 2010, with annual rates exceeding demand, though long-term donor outcomes show elevated risks of health deterioration, including and in up to 60% of paid donors due to inadequate postoperative care. Empirical data from this sole national example indicate that payments address supply shortages where altruistic donation falls short, but the system's reliance on low-income vendors raises questions about whether the net increase in viable organs offsets quality declines from donors with preexisting conditions. Experimental studies, including controlled surveys and hypothetical choice scenarios, consistently demonstrate that direct monetary rewards—such as $1,000 to $10,000—significantly elevate stated willingness to donate compared to non-monetary or charitable alternatives, with one analysis finding a 20-30% uplift in donor registration rates under conditions. Economic modeling further supports , projecting that incentives of $12,000 per deceased donor could boost donation rates by 5-10%, yielding net healthcare savings of $38,000 per additional transplant by averting dialysis costs averaging $80,000 annually per patient, with total societal gains up to $169,000 when factoring reduced mortality. These projections align with broader supply-demand analyses indicating that regulated payments could eliminate U.S. organ queues, which exceed 100,000 patients, by increasing cadaveric yields sufficiently to match transplant needs without relying solely on . Critics contend that incentives may erode intrinsic motivations for donation, potentially yielding no net supply gain or even reductions if perceived as commodifying human tissue, though empirical counterevidence from Iran's sustained transplant volumes refutes widespread crowding-out effects. Limited field data from partial reimbursements, such as lost-wage coverage in some U.S. pilots, show modest upticks in living donor participation (e.g., 10-15% higher follow-through rates), but full-scale financial trials remain absent due to regulatory prohibitions, leaving inferences reliant on extrapolations from regulated markets and simulations rather than randomized controls. Overall, available evidence tilts toward incentives enhancing supply in shortage-prone systems, albeit with implementation challenges in ensuring donor safeguards to maintain organ viability.

Black Markets and Trafficking Realities

The global shortage of organs for transplantation, with over 150,000 individuals awaiting transplants annually alone and similar disparities elsewhere, creates incentives for illegal markets where outstrips legal supply. Estimates from the indicate that 5-10% of transplants worldwide involve organs obtained through illicit means, including trafficking, driven by economic desperation in donor populations and willingness to pay among affluent recipients. These markets operate through networks that exploit vulnerabilities, often involving , , or outright force, with victims predominantly from low-income or marginalized groups who receive minimal compensation relative to the high prices charged to buyers. Documented hotspots include , where cross-border trafficking from has proliferated, with brokers using fraud and poverty to procure from rural donors, as evidenced by cases in 2025 where entire villages reported widespread unilateral nephrectomies without adequate medical follow-up. In , despite a 2006 ban on organ sales, illegal procurement persisted, including allegations of harvesting from executed prisoners until reforms in 2015 aimed to shift to voluntary donation systems, though enforcement challenges remain. and have been centers for kidney trade, with reports of coerced removals from refugees and laborers in operations as recent as 2014, facilitated by weak regulatory oversight. African regions, particularly North and West , as well as Kenya's area, serve as emerging nodes, where migrants and locals are targeted for organ removal amid trafficking routes, per assessments in 2021. Trafficking modalities typically involve intermediaries—brokers, clinics, and surgeons—who promise donors payments of $1,000–$5,000 for kidneys, while recipients pay $50,000–$200,000, yielding profits for networks estimated in billions annually, though precise figures are elusive due to underground operations. Victims face severe post-operative risks, including infection, hypertension, and reduced lifespan, often without access to care, as legal prohibitions fail to deter demand from transplant tourism. United Nations Office on Drugs and Crime reports highlight organ removal as a growing subset of human trafficking, distinct from but intersecting with labor and sex exploitation, with cases involving induced consent under duress or direct abduction. Efforts like the 2008 Declaration of Istanbul, endorsed by transplant societies, condemn such practices and advocate for international cooperation, yet persistent shortages undermine eradication, as evidenced by ongoing detections in INTERPOL operations.

Religious and Cultural Views

Positions of Major Religions

Christianity. The endorses organ donation as a "noble and meritorious act" expressing solidarity, provided it respects the dignity of the donor and recipient, as affirmed in the and papal addresses. Protestant denominations, including Evangelicals and Presbyterians, generally permit donation without doctrinal opposition, viewing it as a personal matter of aligned with charity, though decisions rest with individuals and churches. The considers organ donation permissible as an act of love, but not obligatory, emphasizing no coercion and preservation of post-death where possible; the Greek Orthodox Archdiocese, for instance, supports it if it aids the dying without hastening death. Islam. Islamic jurisprudence permits organ donation and transplantation to preserve life, as ruled in fatwas from bodies like the Fiqh Council of , which in September 2024 declared it allowable when conducted ethically, without commercialism, and as an act of ongoing charity (sadaqah jariyah), provided the donor faces no undue harm. Sunni scholars similarly endorse it under necessity, balancing bodily sanctity with the duty to save lives, though some require reversible death certification and prohibit selling organs. Judaism. authorizes organ donation to fulfill , the imperative to save lives that supersedes most commandments, including bodily wholeness after death; rabbinic authorities permit both living and cadaveric donation if it directly averts mortal danger, though debates persist on criteria and prioritization of Jewish recipients to avoid enmity. Hinduism. Hindu scriptures impose no prohibition on organ donation, which aligns with daan (selfless giving) and dharma (duty), allowing it as an individual's choice without conflicting with beliefs in reincarnation or ritual cremation, as affirmed by the Hindu Temple Society of North America. Buddhism. Buddhist teachings neither mandate nor forbid organ donation, deferring to personal conscience while praising it as an expression of compassion (karuna) and generosity (dana) to alleviate suffering, consistent across Theravada and other traditions, though some emphasize undisturbed dying processes. Sikhism. Sikh doctrine supports organ donation as nishkam seva (selfless service) and the ultimate act of giving, with no restrictions on the body post-death, as the physical form holds no eternal significance; Sikh organizations encourage registration to aid others in line with sarbat da bhala (welfare for all).

Cultural Influences on Participation Rates

Cultural norms regarding , , and communal obligations exert substantial influence on organ donation rates worldwide. Societies that prioritize the preservation of the corpse for spiritual continuity or ancestral exhibit markedly lower participation; for instance, in East Asian contexts, Confucian-influenced traditions viewing the body as indivisible for posthumous rites contribute to reluctance, with 75.6% of Chinese and Korean American respondents in a 2019 survey citing traditional views as the primary cause of organ shortages. Similarly, among Native American populations, cultural emphases on holistic body-spirit connections and historical marginalization from healthcare systems correlate with donation rates substantially below national averages, driven by limited awareness and traditional taboos against . In sub-Saharan African settings, entrenched myths portraying as or exploitation, alongside generalized of medical authorities, suppress deceased rates, often keeping them under 1 per million population in countries like and as of recent assessments. These barriers persist despite potential matches, as cultural narratives frame as a threat to familial lineage or postmortem repose, exacerbating shortages where end-stage renal disease prevalence is high. In multicultural immigrant communities, such as culturally and linguistically diverse groups in , comprises only 15% of totals despite representing over 30% of waitlist candidates, attributable to intergenerational transmission of homeland skepticism toward institutional medicine. Conversely, individualistic Western cultures foster higher engagement through framing donation as an extension of personal agency and societal reciprocity, though disparities endure; U.S. data from 2006 indicate sign donor cards at 39.1% versus 64.9% for whites, linked to legacies of medical experimentation fostering enduring suspicion independent of religious . Arab-based populations show age-stratified support at 54% among youth but 47% among elders, reflecting prioritizing family consensus over individual . Such variances underscore that while policies like systems elevate registration—exceeding 90% in select European nations—sustained hinges on eroding culturally embedded fears without undermining voluntary .

Persistent Challenges

Waiting Lists, Shortages, and Mortality

In the United States, as of May 2025, more than 103,000 individuals are on the national organ transplant waiting list, with kidneys comprising the majority of cases at approximately 85,000 patients. Active candidates number around 61,000, reflecting both active and inactive statuses due to temporary health fluctuations or prioritization pauses. Globally, precise aggregates are elusive, but in Europe, waiting lists contributed to 7,054 deaths in 2023 alone, averaging 19 fatalities daily. The organ shortage stems from demand outpacing supply, driven by rising end-stage organ failure from aging populations, , , and alcohol-related , alongside expanded transplant eligibility criteria. In the , annual transplants reached over 45,000 in 2023, yet every 10 minutes a new patient joins the list, perpetuating the gap. Deceased donor recovery has increased, particularly via donation after circulatory death, but donor tissue quality declines with demographic aging and comorbidities, limiting usable organs. Mortality on waiting lists remains stark: in the , 13 patients die daily awaiting transplants, down from 16 per day previously, equating to about 5,600 annual deaths. candidates face median waits of years, often relying on dialysis, which carries its own mortality risks exceeding 20% annually for some demographics. Systemic factors, including barriers and allocation inefficiencies, exacerbate these outcomes without fully resolving underlying supply constraints.

Systemic Inefficiencies in Allocation

In the United States, organ allocation is managed by the (UNOS) under the Organ Procurement and Transplantation Network (OPTN), prioritizing recipients based on medical urgency, biological compatibility (e.g., , tissue matching), wait time, and geographic proximity to minimize cold ischemia time—the duration organs can safely remain outside the body, typically limited to 4-6 hours for hearts and lungs, 12-18 hours for livers, and up to 36 hours for kidneys. Despite policy shifts toward broader national sharing since 2016 for livers and 2019-2021 for kidneys to address local disparities, systemic inefficiencies persist, including variable organization (OPO) performance, logistical barriers in transportation, and overly conservative discard criteria that result in thousands of viable organs going unused annually. Geographic disparities exacerbate these issues, as OPO service areas—originally designed around metropolitan centers—create uneven supply-demand imbalances; for instance, regions with higher rates of trauma-related deaths export more organs, while rural or low-donation areas face prolonged wait times, with median wait times varying from under 2 years in some donor service areas (DSAs) to over 5 years in others as of 2023 . Transportation challenges compound this, as logistics, air traffic delays, and regulatory hurdles limit efficient cross-country shipping; UNOS reports that in 2023, over 8,000 kidneys were discarded partly due to failure to match with specialized centers , despite potential viability for high-risk recipients. High discard rates highlight matching inefficiencies, with approximately 21% of recovered deceased-donor kidneys (around 5,000 organs) discarded in 2023, often citing "no recipient located" (up to 60% during surges) or findings deemed suboptimal, though studies indicate many could succeed in expanded criteria transplants. Liver discards, at about 10-15%, frequently stem from similar organ quality assessments or logistical mismatches, contributing to an estimated 28,000 unused organs yearly across all types. These inefficiencies directly impact mortality, with 13 patients dying daily on waitlists in 2023—down from 17 in prior years but still reflecting failures in allocation speed and equity—while over 100,000 remain listed amid rising transplants (46,632 in 2023). Bureaucratic and data-sharing gaps further hinder optimization; fragmented IT s across limit real-time matching, and performance metrics tied to local outcomes incentivize conservative practices over national utility, as evidenced by OPTN audits revealing inconsistent adherence to acuity-based models like the Lung Allocation Score or Kidney Donor Profile Index. Reforms, such as continuous distribution algorithms piloted in 2021, aim to minimize DSA boundaries but face resistance from centers benefiting from local priority, perpetuating a where empirical evidence of viable organ waste underscores the need for causal analysis of procurement-transport-allocation chains.

Key Controversies

Flaws in the Dead Donor Rule

The dead donor rule (DDR), which mandates that vital organs be procured only from individuals declared dead and that procurement itself must not cause death, has faced scrutiny for relying on contested definitions of death, particularly . Critics argue that , established by the 1968 Harvard criteria requiring irreversible cessation of all brain functions including the , does not equate to the biological death of the organism as a whole, as brain-dead patients often maintain circulation, respiration via ventilators, and hormonal regulation, exhibiting characteristics indistinguishable from life in non-brain functions. This discrepancy undermines the DDR's foundational assumption, as procurement from such patients effectively hastens systemic disintegration, blurring the line between death declaration and organ removal. A core flaw lies in the rule's origins as a legal expedient rather than a robust ethical or biological standard; formulated in the to mitigate liability fears among transplant surgeons, the DDR equated with without empirical consensus on its equivalence to cardiopulmonary cessation, leading to accusations of a "" that prioritizes organ availability over precise of death. In practice, this has fostered conflicts of interest, where clinicians involved in may influence death declarations, as evidenced by cases of premature rulings in potential donors to expedite harvesting, eroding public trust despite safeguards like independent evaluations. Furthermore, the DDR constrains donation after circulatory death (DCD) protocols by imposing mandatory waiting periods—typically 2–5 minutes after —to confirm irreversible cessation, during which organs suffer ischemic damage, reducing viability and exacerbating shortages; data from U.S. transplant registries indicate that DCD kidneys, for instance, yield 10–20% lower long-term graft survival compared to brain-dead donors due to this delay. Proponents of reforming or abandoning the DDR, such as bioethicists Robert Truog and Franklin Miller, contend that the rule arbitrarily limits organ supply without moral justification, as patients with catastrophic brain injury who to (or via surrogates) could have organs removed prior to formal declaration, followed by withdrawal of , thereby aligning with patient-centered end-of-life choices rather than rigid deontic constraints. Empirical surveys support this critique, with a 2015 U.K. study finding 60–70% public acceptance for scenarios explicitly violating the DDR under conditions of , suggesting the rule's absolutism may perpetuate thousands of preventable on waiting lists annually—over 17,000 in the U.S. alone in —without commensurate ethical gains. Recent innovations like thoracoabdominal normothermic regional perfusion (ta-NRP), which restarts circulation post-declaration to improve organ quality, have intensified debates by arguably contravening the DDR's prohibition on interventions hastening , prompting opposition from bodies like the while highlighting the rule's incompatibility with advancing perfusion techniques.

Risks and Exploitation in Living Donation

Living kidney donation, the most common form of living organ donation, carries perioperative risks including , , and complications, with major complication rates reported at 2-5% in screened donors. Long-term risks include a modestly elevated lifetime incidence of end-stage renal disease (ESRD), estimated at 0.9% for donors versus 0.3% in matched healthy non-donors, alongside increased of and reduced . Female donors face heightened risks of and in subsequent pregnancies, with ratios up to 2.0 in some cohorts. Mortality post-nephrectomy remains low, at approximately 0.03% within 90 days, though some studies indicate a small excess long-term mortality emerging after 15 years. Living liver donation entails greater procedural complexity and risks, with perioperative mortality rates of 0.1-0.2%—roughly 1 death per 500-1000 donors—and major complication rates ranging from 20-40%, including bile leaks, vascular thrombosis, and hepatic insufficiency. Donors often experience prolonged recovery, with readmission rates exceeding 10% within 90 days, and long-term effects may include chronic fatigue or marginal liver regeneration deficits in a subset. Financial burdens are common across living donations, with donors incurring average costs of 5,0005,000-10,000 for travel, lost wages, and care, despite regulatory efforts to mitigate these in some jurisdictions. Exploitation arises from subtle in familial or directed donations, where donors may face emotional or financial dependency, undermining true voluntariness despite screening protocols. In unregulated contexts, particularly in low-income regions, living donors—often from impoverished backgrounds—are deceived or compelled into selling organs for sums far below , receiving less than 10% of brokered payments while brokers and recipients profit disproportionately. Organ trafficking networks exploit this vulnerability, with victims subjected to non-consensual removals or post-harvest abandonment, leading to severe sequelae like , renal failure, or ; reports indicate such illicit activities may underlie up to 10% of global transplants, disproportionately affecting migrants and the economically disadvantaged. The Declaration of Istanbul highlights how poverty-driven sales perpetuate exploitation, as donors endure lifelong health impairments without commensurate benefits or protections. Presumed , also known as opt-out , operates on the principle that individuals are deemed to agree to posthumous organ donation unless they have explicitly registered an objection prior to death. This policy shifts the burden from active affirmation to active refusal, contrasting with opt-in systems requiring explicit . Countries adopting presumed consent include , which implemented it in 1979, and the , which transitioned to an opt-out model effective May 2020. In , the system is paired with a robust national transplant organization emphasizing family consultation, while the UK's model allows family even under presumed . Empirical evidence on presumed consent's effectiveness in boosting donation rates remains inconclusive, with studies showing modest associations rather than clear causation. A 2009 analysis of European data found presumed consent linked to higher deceased donor rates, estimating an increase of about 14-30% after controlling for confounders like healthcare . However, a 2019 modeling study projected only a 5% rise in U.S.-style systems, while a 2024 review of policy shifts in five countries concluded that opt-out defaults do not significantly elevate rates when isolating the consent mechanism from concurrent improvements in processes. High-performing nations like achieve 40-50 donors per million population annually, but this correlates more strongly with dedicated coordinators and public education than consent type alone; opt-in countries with strong systems, such as the U.S. (peaking at 40 per million in 2023 via targeted reforms), demonstrate comparable outcomes without presumed consent. Critics argue that presumed consent undermines individual by presuming agreement without affirmative evidence, potentially treating silence as in violation of first-principles for . Ethical analyses highlight that true requires informed, voluntary choice, and opt-out systems exploit decision inertia—where most people fail to register objections due to or unawareness—effectively coercing donation through default. A 2012 review contended that such policies risk eroding in healthcare institutions, as without explicit donor intent may foster perceptions of state overreach or "" of organs, echoing qualitative findings where participants viewed unobjected removal as non-consensual appropriation. Coercion concerns extend to subtle pressures on families and systemic incentives. Even in presumed consent jurisdictions, families often override defaults, with veto rates up to 10-20% in , indicating that presumed agreement does not align with decedents' unspoken wishes and places emotional burdens on survivors. Broader critiques warn of a toward mandated choice or explicit mandates, where the state claims property rights over bodies to serve utilitarian ends, potentially disincentivizing advance directives and normalizing non-consensual harvesting in vulnerable populations unaware of mechanisms. guidelines stipulate that presumed consent is ethically viable only with proven widespread awareness, a condition unmet in many implementations where registration rates remain low (e.g., under 10% opt-outs in early trials). These issues underscore tensions between collective organ needs and individual rights, with empirical data suggesting presumed consent's gains, if any, come at the cost of attenuated personal agency rather than through genuine preference revelation.

Emerging Alternatives

Xenotransplantation Progress

Xenotransplantation, the transplantation of organs or tissues from non-human species to humans, has advanced primarily through of porcine donors to mitigate immunological barriers such as hyperacute rejection and porcine endogenous retroviruses (PERVs). Pigs are favored due to physiological similarities with human organs, including size-compatible kidneys, hearts, and livers. Key modifications include CRISPR-Cas9 editing to eliminate the alpha-1,3-galactosyltransferase gene (responsible for the alpha-Gal epitope triggering immediate rejection), insertion of human complement-regulatory proteins, coagulation factors, and cytoprotective genes, alongside inactivation of PERVs to prevent viral transmission. Recent donor pigs feature 10 or more edits; for instance, eGenesis' EGEN-2784 kidneys incorporate 69 edits, including 59 targeting integrated porcine viruses. Milestones in clinical application began with cardiac xenotransplants. In January 2022, a genetically modified heart (with 10 edits from Revivicor) was transplanted into David Bennett at the University of , enabling survival for two months before unrelated to hyperacute rejection. Subsequent preclinical studies in nonhuman primates have achieved heart survivals exceeding one year, informing human protocols. By 2025, cardiac remains experimental, with focus shifting to renal applications amid regulatory progress. Renal xenotransplants represent the most rapid progress, driven by urgent shortages. In March 2024, performed the first living-recipient pig transplant using a Revivicor organ with 10 edits; the functioned without immediate rejection until the patient's from unrelated complications three days later. A 2024 procedure on Towana Looney sustained function, followed by a 2025 transplant at the same institution. As of September 2025, a 67-year-old recipient of an eGenesis pig achieved over six months' survival without dialysis, marking the longest documented human-pig function and demonstrating graft viability under . The U.S. (FDA) cleared investigational new drug applications in early 2025 for phase 1/2/3 trials by eGenesis and United Therapeutics, with initial procedures anticipated mid-year, evaluating safety and efficacy in end-stage renal disease patients ineligible for allotransplants. Hepatic emerged in 2025 with a world-first procedure on October 8, using a 10-edit liver that supported human circulation for an extended period without acute failure, as reported by the European Association for the Study of the Liver. This brain-dead recipient model validated short-term compatibility, paving the way for living-donor trials. Overall, these developments signal a transition from compassionate-use cases to structured trials, with organ function in humans now routinely extending weeks to months, though long-term outcomes (beyond one year) remain unproven and dependent on managing chronic rejection and toxicities.

Bioengineering and Other Innovations

Bioengineering approaches to organ replacement primarily involve techniques that utilize , stem cells, and advanced fabrication methods to create functional tissues or whole organs compatible with the recipient, thereby addressing immunological rejection and donor shortages. , a foundational method, entails perfusing donor organs with detergents to remove cellular components while preserving the (ECM) architecture, which serves as a natural for recellularization with patient-derived cells. This process has successfully produced acellular scaffolds for hearts, livers, and kidneys in preclinical models, with recellularization using endothelial and parenchymal cells demonstrating partial vascular and functional restoration in and porcine studies. However, challenges persist in achieving uniform cell distribution and long-term viability, as incomplete recellularization can lead to or post-implantation. Three-dimensional (3D) bioprinting represents another key innovation, layering bioinks composed of cells, hydrogels, and growth factors to construct tissue constructs with precise . Advances include extrusion-based printing of vascularized organoids and liver tissues that exhibit metabolic activity, with recent preclinical work demonstrating bioprinted scaffolds for solid organs supporting cell engraftment. Clinical applications remain limited to simpler structures; for instance, autologous bioprinted skin and have entered early human trials for and joint repair, but full organ bioprinting faces hurdles in scalability, nutrient diffusion beyond 200-500 micrometers, and mechanical integrity matching native tissues. Induced pluripotent stem cells (iPSCs) integrated into bioprinting enable patient-specific organs, reducing rejection risks, though tumorigenicity and ethical sourcing concerns require rigorous preclinical validation. Regenerative medicine innovations extend to organoids—miniature, self-organizing tissue models derived from stem cells—that mimic organ physiology for transplantation or testing. Intestinal organoids transplanted into animal models have restored absorptive functions, with human trials exploring their use for gut repair in . Similarly, renal organoids from iPSCs show glomerular filtration potential , paving the way for bioengineered kidney subunits to supplement dialysis rather than full replacement. As of 2025, no fully bioengineered human organs have achieved regulatory approval for routine transplantation, with progress confined to xenocompatible scaffolds and partial organ analogs; experts project 10-20 years for viable whole-organ clinical deployment, contingent on resolving vascularization and via combined decellularization-bioprinting hybrids. These developments, while promising, underscore the empirical gap between laboratory constructs and clinical efficacy, necessitating large-scale animal-to-human translational studies.

Policy and Technological Paths Forward

Efforts to reform and allocation policies include modernizing the Organ Procurement and Transplantation Network (OPTN) to enhance efficiency and accountability, with updates announced by the (HRSA) in September 2025 emphasizing reinforced oversight and data transparency. Legislative proposals such as the Removing Burdens from Organ Donation Act, introduced in July 2025, aim to streamline procedures for donations after circulatory death (DCD), which increased 23.5% from 2023 to 7,280 donors in 2024, by reducing regulatory hurdles without altering consent frameworks. Presumed consent policies, adopted in countries like , correlate with higher donation rates—up to 5% increases in deceased donations per some models—but empirical reviews indicate they alone do not consistently explain international variations, as systemic factors like family override rates and procurement infrastructure play larger roles. Incentive-based approaches remain debated, with proposals for non-financial rewards like funeral expense reimbursements or donor medals of honor tested in pilot programs to boost supply without commodifying organs, though evidence on their impact is limited and ethical concerns persist regarding coercion. Recent U.S. initiatives, such as the bipartisan End Kidney Deaths Act proposed in August 2025, suggest refundable tax credits up to $10,000 annually for five years to living kidney donors, potentially increasing donations while addressing financial disincentives like lost wages. These policies prioritize regulated, non-cash incentives to align with ethical standards prohibiting direct payments, as outlined by OPTN guidelines. Technological advancements focus on extending organ viability and optimizing allocation, including machine perfusion systems that rehabilitate marginal donor organs, enabling greater utilization and reducing discard rates observed in static cold storage. Innovations like supercooling and vitrification preserve organs beyond traditional limits, with research in 2025 exploring nanotechnology for cellular protection during transport. Artificial intelligence and big data analytics are emerging to predict graft outcomes and match donors-recipients more precisely, potentially lowering rejection risks by analyzing genomic and immunological data in real-time. Integrated paths forward advocate policy frameworks that incentivize technology adoption, such as federal grants for devices and standardized international data-sharing protocols to facilitate cross-border transplants, addressing global shortages where over 100,000 patients await organs in the U.S. alone as of 2025. Reforms emphasizing performance-based funding for organizations (), as proposed by UNOS, could combine with AI-driven allocation to minimize inefficiencies, though requires rigorous to ensure equitable access without exacerbating disparities.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.